WO2017067530A2 - 一种治疗前列腺癌的组合、药物组合物及治疗方法 - Google Patents

一种治疗前列腺癌的组合、药物组合物及治疗方法 Download PDF

Info

Publication number
WO2017067530A2
WO2017067530A2 PCT/CN2017/073380 CN2017073380W WO2017067530A2 WO 2017067530 A2 WO2017067530 A2 WO 2017067530A2 CN 2017073380 W CN2017073380 W CN 2017073380W WO 2017067530 A2 WO2017067530 A2 WO 2017067530A2
Authority
WO
WIPO (PCT)
Prior art keywords
combination
prednisone
abiraterone
galeterone
odm201
Prior art date
Application number
PCT/CN2017/073380
Other languages
English (en)
French (fr)
Other versions
WO2017067530A3 (zh
Inventor
戈传生
廖柏松
李文成
Original Assignee
康朴生物医药技术（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES17718469T priority Critical patent/ES2899372T3/es
Priority to JP2019543848A priority patent/JP6773915B2/ja
Application filed by 康朴生物医药技术（上海）有限公司 filed Critical 康朴生物医药技术（上海）有限公司
Priority to RU2019127449A priority patent/RU2733950C1/ru
Priority to EP17718469.4A priority patent/EP3581182B1/en
Priority to CN201780085859.9A priority patent/CN110248662B/zh
Priority to PL17718469T priority patent/PL3581182T3/pl
Priority to NZ756412A priority patent/NZ756412B2/en
Priority to KR1020197026618A priority patent/KR102125661B1/ko
Priority to AU2017202864A priority patent/AU2017202864B2/en
Priority to CA3053805A priority patent/CA3053805C/en
Priority to PCT/CN2017/073380 priority patent/WO2017067530A2/zh
Priority to US16/482,549 priority patent/US20200000776A1/en
Publication of WO2017067530A2 publication Critical patent/WO2017067530A2/zh
Publication of WO2017067530A3 publication Critical patent/WO2017067530A3/zh
Priority to ZA2019/05222A priority patent/ZA201905222B/en
Priority to US17/325,468 priority patent/US20210267946A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a combination, a pharmaceutical composition and a method of treatment for treating prostate cancer.
  • Prostate cancer is a common malignant tumor of the male reproductive system. According to the World Health Organization's International Agency for Research on Cancer, the number of newly diagnosed prostate cancer patients in the world was 1.1 million in 2012, accounting for 15% of the total number of new cancer cases, making it the second most common cancer among men worldwide. In the United States, the incidence of prostate cancer ranks first among all malignant tumors, and mortality ranks second, second only to lung cancer. Although the incidence of prostate cancer patients in China is much lower than that in Western countries, it has shown a significant growth trend in recent years. It has ranked first in male urinary tumors and found to be mostly in advanced stage.
  • Prostate cancer cells need androgen support, including testosterone, to grow. Therefore, the targeted therapeutic strategy for prostate cancer is mainly directed to the synthesis of androgen and its binding to androgen receptors.
  • Enzalutamide a prostate cancer drug approved by the US FDA in August 2012, is a small molecule androgen receptor antagonist that ultimately inhibits males by competitively inhibiting the binding of androgens to their receptors.
  • the hormone receptor signaling pathway in turn, achieves the effect of treating castration-tolerant prostate cancer.
  • Enzalutamide also has some side effects in clinical research, such as weakness or fatigue, low back pain, diarrhea, joint pain, hot flashes, tissue swelling, musculoskeletal pain, headache, upper respiratory tract infection, dizziness, oppression Spinal cord and cauda equina syndrome, muscle weakness, difficulty sleeping, lower respiratory tract infection, hematuria, tingling, anxiety and high blood pressure.
  • the present invention provides a combination, a pharmaceutical composition and a method of treatment for treating prostate cancer.
  • the combination, pharmaceutical composition, and treatment method for treating prostate cancer of the present invention can more effectively inhibit prostate cancer.
  • the present invention provides a combination for treating prostate cancer comprising a benzoheterocyclic compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a solvate, a crystal form, a cocrystal, a stereoisomer, One of an isotope compound, a metabolite, and a prodrug, and an androgen receptor pathway modulator;
  • n1 is 0 or 1;
  • L 1 and L 3 are independently CH 2, CHD, CD 2, or
  • L 2 is CD 2 , CHD or CH 2 ;
  • X is NH, ND or O
  • R 1 , R 2 and R 3 are independently H or D;
  • R 4 is H, D, CH 3 , CH 2 D, CHD 2 or CD 3 ;
  • R 5 , R 6 , R 7 , R 8 and R 9 are independently H or D;
  • carbon marked with * is not Symmetric center
  • R 10 is H, D or Wherein R 1 ', R 2 ', R 3 ', R 4 ' and R 5 ' are independently selected from H, D, or substituted or unsubstituted (C 1 -C 12 ) alkyl;
  • the substituent in the substituted (C 1 -C 12 )alkyl group is selected from one or more of the following groups: D, (C 2 -C 20 )heterocycloalkyl, deuterated (C 2 - C 20 )heterocycloalkyl, (C 1 -C 12 )alkyl substituted (C 2 -C 20 )heterocycloalkyl or deuterated (C 1 -C 12 )alkyl substituted (C 2 -C 20 a heterocycloalkyl group;
  • n1 When in the general formula (I), n1 is 0, X is NH or ND, and L 1 is CH 2 , CHD or CD 2 ; L 3 is When R 10 is H or D;
  • n1 is 0, X is NH or ND, and L 1 is And L 3 is When R 10 is H or D;
  • L 1 is CH 2 , CHD or CD 2 , and L 3 is When R 10 is as described
  • D represents deuterium-enriched hydrogen
  • H represents non-deuterium-enriched hydrogen
  • the androgen receptor pathway modulator is selected from one of the following compounds:
  • the asymmetric center preferably means (S) configuration carbon, (R) configuration carbon or racemate.
  • the Z is preferably any of the following structures:
  • Z is better for the following structure Among them, the carbon marked with * is an asymmetric center, and the definitions of the asymmetric centers, H and D are as described above.
  • the (C 2 -C 20 ) heterocycloalkyl group the deuterated (C 2 -C 20 ) heterocycloalkyl group, the (C) 1 -C 12 )alkyl-substituted (C 2 -C 20 )heterocycloalkyl or substituted (C 2 -C 12 )alkyl substituted (C 2 -C 20 )heterocycloalkyl
  • the (C 2 -C 20 )heterocycloalkyl group is preferably a (C 2 -C 6 )heterocycloalkyl group having a hetero atom of N or O and a hetero atom number of 1-2.
  • the (C 2 -C 6 )heterocycloalkyl group is preferably a morpholinyl group (for example ).
  • the (C 1 -C 12 )alkyl group described in the cycloalkyl group is preferably a (C 1 -C 4 )alkyl group.
  • the (C 1 -C 4 )alkyl group is preferably a methyl group, an ethyl group, a n-propyl group, an isopropyl group, a n-butyl group, an isobutyl group or a t-butyl group.
  • the substituted or unsubstituted (C 1 -C 12 )alkyl group described in the formula (I) according to the invention is preferably a substituted or unsubstituted (C 1 -C 4 )alkyl group.
  • the substituted or unsubstituted (C 1 -C 4 )alkyl group is preferably a substituted or unsubstituted methyl group, a substituted or unsubstituted ethyl group, a substituted or unsubstituted n-propyl group, a substituted or unsubstituted group.
  • substituted (C 1 -C 4 ) alkyl group is preferably
  • the benzoheterocyclic compound represented by the formula (I) according to the present invention is preferably any one of the following compounds:
  • the benzoheterocyclic compound represented by the formula (I) is selected from the group consisting of B001, F001, K001 or D108.
  • the androgen receptor pathway modulator is any one of the following compounds: AR1-1, AR1-2, AR2-1, AR2-2, AR2-3, AR2- 4. AR2-5, AR3-1, AR3-2, AR3-3, AR3-4.
  • the combination preferably comprises a benzoheterocyclic compound of the formula (I) and an androgen receptor pathway modulator: the benzene of the formula (I)
  • the heterocyclic compound is selected from B001, F001, K001 or D108;
  • the androgen receptor pathway regulator is selected from the group consisting of AR1-1, AR1-2, AR1-3, AR1-4, AR2-1, AR2-2. AR2-3, AR2-4, AR2-5, AR2-6, AR2-7, AR2-8, AR2-9, AR2-10, AR2-11, AR2-12, AR2-13, AR2-14, AR2- 15.
  • the androgen receptor pathway modulator Preferably selected from the group consisting of AR1-1, AR1-2, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR3-1, AR3-2, AR3-3 and AR3-4 One.
  • the combination is more preferably any combination of the following: "B001 or F001 or Combination of K001 or D108" and AR1-1, “B001 or F001 or K001 or D108" and AR1-2 combination, “B001 or F001 or K001 or D108” and AR1-3 combination, “B001 or F001 or K001 or Combination of D108" and AR1-4, “B001 or F001 or K001 or D108” and AR2-1 combination, “B001 or F001 or K001 or D108” and AR2-2 combination, “B001 or F001 or K001 or D108” Combination with AR2-3, combination of "B001 or F001 or K001 or D108” and AR2-4, "B001 or F001 or K001 or D108” and combination of AR2-5, "B001 or F001 or K001 or D108” and AR2 a combination of -6, a combination of "B001 or F001 or K001 or D108” and AR2-7, a combination of "B001 or F001 or K001 or D108” and AR2 a combination of -6
  • B001 or F001 or K001 or D108 represents a combination of B001 and AR1-1, a combination of F001 and AR1-1, a combination of K001 and AR1-1, Or, a combination of D108 and AR1-1, those skilled in the art can understand the meanings indicated by the other combinations described above based on the explanation.
  • the combination of the present invention may further comprise other therapeutic agents selected from the group consisting of abiraterone, abiraterone acetate, Galeterone, ODM201, Prednisone, abiraterone and prednisone. Any of abiraterone acetate and prednisone, Galeterone and prednisone, and, ODM201 and prednisone.
  • the combination of the present invention preferably comprises a benzoheterocyclic compound represented by the formula (I), androgen receptor Road regulators and other therapeutic agents: the benzoheterocyclic compound represented by the formula (I) is selected from B001, F001, K001 or D108; the androgen receptor pathway regulator is selected from the group consisting of AR1-1, AR1-2, AR1-3, AR1-4, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR2-6, AR2-7, AR2-8, AR2-9, AR2- 10.
  • the benzoheterocyclic compound represented by the formula (I) is selected from B001, F001, K001 or D108
  • the androgen receptor pathway regulator is selected from the group consisting of AR1-1, AR1-2, AR1-3, AR1-4, AR2-1, AR2-2, AR2-3, AR2-4, AR2-5, AR2-6, AR2-7, AR2-8, AR2-9, AR2- 10.
  • said androgen receptor pathway modulator is preferably selected from the group consisting of AR1-1, AR1-2, AR2-1, AR2-2, AR2-3, AR2-4, AR2 -5, one of AR3-1, AR3-2, AR3-3 and AR3-4; said other therapeutic agent selected from the group consisting of abiraterone, abiraterone acetate, Galeterone, ODM201, prednisone (Prednisone) ), abiraterone and prednisone, abiraterone acetate and prednisone, Galeterone and prednisone, and, ODM201 and prednisone
  • the combination is preferably any combination of the following: “B001 or F001 or K001 or D108" and a combination of AR1-1 and Abitrone, “B001 or F001 or K001 or D108” "Combination with AR1-2 and Abiton, “B001 or F001 or K001 or D108” and a combination of AR2-1 and Abiton, “B001 or F001 or K001 or D108” and AR2-2 and Abiton Combination, “B001 or F001 or K001 or D108” and a combination of AR2-3 and Abitron, “B001 or F001 or K001 or D108” and a combination of AR2-4 and Abitron, “B001 or F001 or K001 or D108 “Combination with AR2-5 and Abiton, "B001 or F001 or K001 or D108” and a combination of AR3-1 and Abiton, "B001 or F001 or K001 or D108” and AR3-2 and Abiton Combination, "B001 or F001 or K001 or D
  • the components of the combination may be used simultaneously or separately (eg, sequentially); when the components of the combination are used simultaneously, the components of the combination may be uniformly mixed (ie, the components mixture).
  • the term "component” means a component in the combination of the present invention, that is, a compound of the formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope thereof
  • a compound of the formula (I) a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope thereof
  • the invention also provides a pharmaceutical composition comprising the combination described above and one or more pharmaceutical excipients.
  • the pharmaceutical composition provided by the present invention may comprise a benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic or stereoisomer thereof. , one of an isotope compound, a metabolite, and a prodrug, the above-described androgen receptor pathway modulator, and one or more pharmaceutically acceptable excipients.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer
  • a pharmaceutically acceptable salt solvate, crystal form, eutectic, stereoisomer
  • a body an isotope compound, a metabolite, and a prodrug
  • the above-described androgen receptor pathway modulator the other therapeutic agent described above
  • one or more pharmaceutical excipients comprising the benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer
  • the pharmaceutical excipients may be those excipients widely used in the field of pharmaceutical production.
  • the excipients are primarily used to provide a safe, stable, and functional pharmaceutical composition, and may also provide means for the subject to be dissolved at the desired rate after administration, or to promote the subject's activity after administration of the composition.
  • the ingredients are effectively absorbed.
  • the pharmaceutical excipient can be an inert filler or provide a function, such as stabilizing the overall pH of the composition or preventing degradation of the active ingredients of the composition.
  • the pharmaceutical excipient may include one or more of the following excipients: binder, suspending agent, emulsifier, diluent, filler, granulating agent, adhesive, disintegrant, lubricant, anti-adhesion Agents, glidants, wetting agents, gelling agents, absorption delaying agents, dissolution inhibitors, reinforcing agents, adsorbents, buffers, chelating agents, preservatives, coloring agents, flavoring agents, and sweeteners.
  • excipients binder, suspending agent, emulsifier, diluent, filler, granulating agent, adhesive, disintegrant, lubricant, anti-adhesion Agents, glidants, wetting agents, gelling agents, absorption delaying agents, dissolution inhibitors, reinforcing agents, adsorbents, buffers, chelating agents, preservatives, coloring agents, flavoring agents, and sweeteners.
  • compositions known in the art include, but are not limited to, conventional mixing, dissolving, granulating, emulsifying, pulverizing, encapsulating, embedding, or lyophilizing processes.
  • the pharmaceutical composition of the present invention may be obtained by mixing a benzoheterocyclic compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a solvate, a crystal form, a eutectic, a stereoisomer, an isotope compound, One of metabolites and prodrugs, androgen receptor pathway modulators, and pharmaceutical excipients are prepared.
  • the pharmaceutical composition of the present invention may be prepared by mixing a compound of the formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite, and prodrug thereof.
  • a pharmaceutically acceptable salt solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite, and prodrug thereof.
  • One, androgen receptor pathway modulator, other therapeutic agents, and pharmaceutical excipients are prepared.
  • compositions of the present invention may be formulated for administration in any form, including injection (intravenous), mucosa, oral (solid and liquid preparations), inhalation, ocular, rectal, topical or parenteral (infusion). , injection, implantation, subcutaneous, intravenous, intraarterial, intramuscular) administration.
  • the pharmaceutical compositions of the invention may also be in a controlled release or delayed release dosage form.
  • Solid Examples of oral formulations include, but are not limited to, powders, capsules, caplets, soft capsules, pills, and tablets.
  • liquid preparations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs, and solutions.
  • Examples of the formulation for topical administration include, but are not limited to, an emulsion, a gel, an ointment, a cream, a patch, a paste, a foaming agent, a lotion, a drop, or a serum preparation.
  • preparations for parenteral administration include, but are not limited to, solutions for injection, dry preparations which can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection.
  • Examples of other suitable formulations of the pharmaceutical compositions include, but are not limited to, eye drops and other ophthalmic formulations; aerosols: such as nasal sprays or inhalants; liquid dosage forms suitable for parenteral administration; suppositories and ingots Agent.
  • the present invention also provides a combination kit comprising the pharmaceutical composition A and the pharmaceutical composition B;
  • the pharmaceutical composition A comprises the above-described benzoheterocyclic compound represented by the formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolism thereof.
  • the pharmaceutical composition B comprising the above-described androgen receptor pathway modulator and one or more pharmaceutically acceptable excipients.
  • the combination kit may further comprise a pharmaceutical composition C comprising the other therapeutic agent described above and one or more pharmaceutical excipients.
  • A one of a body, an isotope compound, a metabolite, and a prodrug
  • the "androgen receptor pathway modulator” described in the pharmaceutical composition B and the “others” described in the pharmaceutical composition C
  • Therapeutic agents and the combinations they form are as described above.
  • Each of the pharmaceutical compositions in the combination kit can be used simultaneously or separately (e.g., sequentially).
  • the "pharmaceutical excipient" is as defined above.
  • the term "active ingredient” means an active ingredient in the pharmaceutical composition or combination kit of the present invention, that is, a compound of the formula (I), a pharmaceutically acceptable salt thereof, a solvate, a crystal form, a eutectic, One of a stereoisomer, an isotope compound, a metabolite, and a prodrug, an androgen receptor pathway modulator, other therapeutic agents, or a combination thereof.
  • the above combination, the above pharmaceutical composition, or the above-described combination kit can be used for the prevention and/or treatment of prostate cancer.
  • the prostate cancer is preferably castration-resistant prostate cancer.
  • the present invention provides the benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotopic compound thereof, One of a metabolite and a prodrug for use in the preparation of a medicament for use in combination with an androgen receptor pathway modulator as described above for the prevention and/or treatment of prostate cancer.
  • the present invention also provides the above-described androgen receptor pathway modulator, which is prepared for use in the above formula (I) A drug for preventing and/or treating prostate cancer in combination with a benzoheterocyclic compound, a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite and prodrug thereof Application in .
  • the present invention provides the benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotopic compound thereof, One of a metabolite and a prodrug for use in the manufacture of a medicament for the prevention and/or treatment of prostate cancer in combination with the above-described androgen receptor pathway modulator, and other therapeutic agents described above.
  • the present invention also provides the above-described androgen receptor pathway modulator, which is prepared by using the benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt, a solvate thereof, a crystal form, Use of one of a eutectic, a stereoisomer, an isotope compound, a metabolite, and a prodrug, and other therapeutic agents described above in combination with a medicament for preventing and/or treating prostate cancer.
  • the above-described androgen receptor pathway modulator which is prepared by using the benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt, a solvate thereof, a crystal form, Use of one of a eutectic, a stereoisomer, an isotope compound, a metabolite, and a prodrug, and other therapeutic agents described above in combination with a medicament for preventing and/or treating prostate cancer.
  • the present invention also provides the above other therapeutic agent for preparing a benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt thereof, a solvate, a crystal form, a eutectic, a stereo Use of one of an isomer, an isotope compound, a metabolite, and a prodrug, and a combination of the above-described androgen receptor pathway modulators for preventing and/or treating prostate cancer.
  • a benzoheterocyclic compound represented by the above formula (I) a pharmaceutically acceptable salt thereof, a solvate, a crystal form, a eutectic, a stereo Use of one of an isomer, an isotope compound, a metabolite, and a prodrug, and a combination of the above-described androgen receptor pathway modulators for preventing and/or treating prostate cancer.
  • One of the metabolites and prodrugs, the above-described androgen receptor pathway modulators, and the other therapeutic agents described above may be administered simultaneously or separately (e.g., sequentially).
  • the benzoheterocyclic compound represented by the formula (I) a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotopic compound, metabolite thereof
  • a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotopic compound, metabolite thereof One of the prodrugs, the androgen receptor pathway modulator, the other therapeutic agent, and combinations thereof are as described above.
  • the invention also provides a method of preventing and/or treating prostate cancer comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of the combination described above.
  • the prostate cancer may be castration resistant prostate cancer.
  • the method of preventing and/or treating prostate cancer comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a benzoheterocyclic compound represented by the above formula (I), which is pharmaceutically acceptable One of a salt, a solvate, a crystal form, a eutectic, a stereoisomer, an isotope compound, a metabolite, and a prodrug, and a therapeutically or prophylactically effective amount of the above-described androgen receptor pathway modulator.
  • a benzoheterocyclic compound represented by the above formula (I) which is pharmaceutically acceptable
  • a salt, a solvate, a crystal form, a eutectic, a stereoisomer, an isotope compound, a metabolite, and a prodrug and a therapeutically or prophylactically effective amount of the above-described androgen receptor pathway modulator.
  • the benzoheterocyclic compound represented by the above formula (I) a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite, and prodrug thereof
  • the above-described androgen receptor pathway modulators can be administered simultaneously or separately (e.g., sequentially).
  • the method of preventing and/or treating prostate cancer preferably includes The patient is administered a therapeutically or prophylactically effective amount of the benzoheterocyclic compound represented by the above formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite thereof Or a prodrug, a therapeutically or prophylactically effective amount of the above-described androgen receptor pathway modulator, and a therapeutically or prophylactically effective amount of the above other therapeutic agent.
  • a therapeutically or prophylactically effective amount of the benzoheterocyclic compound represented by the above formula (I) a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite thereof Or a prodrug, a therapeutically or prophylactically effective amount of the above-described androgen receptor pathway modulator, and a therapeutically or prophylactically effective amount of the above other therapeutic agent.
  • benzoheterocyclic compound represented by the above formula (I) a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite, and prodrug thereof
  • the above-described androgen receptor pathway modulators, and the above other therapeutic agents may be administered simultaneously or separately (e.g., sequentially).
  • an isomer, an isotope compound, a metabolite, and a prodrug, the androgen receptor pathway modulator, the other therapeutic agent, and combinations thereof are as described above.
  • the benzoheterocyclic compound represented by the formula (I) and the The molar ratio of the androgen receptor pathway modulator can be selected according to routine practice in the art, for example from 1:0.1 to 1:100, such as from 1:1 to 1:50, such as from 1:1 to 1:10.
  • the amount of the other therapeutic agent is not special
  • the molar ratio of the other therapeutic agent to the androgen receptor pathway modulator may be from 1:0.1 to 1:100, for example from 1:0.5 to 1:50, such as 1:1 to 1: 10.
  • the benzoheterocyclic compound represented by the formula (I) and the The amount of the androgen receptor pathway modulator may be selected according to the routine in the art.
  • the amount of the substance of the benzoheterocyclic compound represented by the formula (I) may be 1-100 ⁇ M, for example, 1-50 ⁇ M, for example, 1-10 ⁇ M.
  • the amount of the substance of the androgen receptor pathway modulator may be 1-300 ⁇ M, for example 1-100 ⁇ M, for example 1-10 ⁇ M.
  • the amount of the other therapeutic agent is not special
  • the amount of substance, such as the other therapeutic agents described may be from 1 to 300 [mu]M, such as from 1 to 100 [mu]M, such as from 1 to 10 [mu]M.
  • the components of the combination of the invention When the components of the combination of the invention are administered to a subject to treat or prevent a disease, disorder or condition, the components of the combination may be administered by the same route or by different routes. Administration can be by any of the routes described herein including, but not limited to, oral, inhalation, injection, ocular, mucosal, rectal, emulsion, liposomal, long-term implantation or sustained release methods.
  • the particular route of administration will depend on the therapeutic agent itself and the formulation, as well as the disease, condition or condition to be prevented or treated. In accordance with the present disclosure, one of ordinary skill in the art has a skill level sufficient to determine its route of administration.
  • the components of the combination of the invention may be administered to the subject over a period of time (dose cycle), thereafter It is a period in which no compound is administered (non-dosing period).
  • dose cycle a period in which no compound is administered
  • non-dosing period a period in which no compound is administered
  • the desired number of dosing cycles and non-dosing cycles can be repeated.
  • the desired length and number of administration cycles or non-dosing cycles will depend on the type and/or severity of the disease, condition or condition being treated or prevented, as well as the gender, age, weight and other parameters of the individual subject ( For example, the biological, physical, and physiological conditions of the individual subject, etc.).
  • the components in the combination of the present invention may be administered to the subject simultaneously over a period of time, and may also be administered to the subject sequentially over a period of time. The level of skill of one of ordinary skill in the art in light of the disclosure herein will be sufficient to determine the appropriate length and number of dosing cycles and/or non
  • Therapeutic methods described herein can be administered to a subject using the components of the combination of the invention using any suitable method, including injection, transmucosal, oral, inhalation, ocular, rectal, long-term implantation, liposomes. , emulsion or sustained release method.
  • the therapeutically or prophylactically effective amount of each component or active ingredient in a combination, pharmaceutical composition or combination kit of the invention may vary from subject to subject, such as for a particular subject, such as Age, diet, health, etc., seeking treatment or prevention of symptoms or the severity of the disease, condition or condition as well as complications and types, preparations used, and the like.
  • a therapeutically or prophylactically effective amount to be administered to a subject to elicit a desired biological or medical response in the subject may be administered to a subject to elicit a desired biological or medical response in the subject.
  • the prophylactically effective amount can be effective less than when the compound of formula (I) of the present invention, a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite or prodrug thereof thereof is not administered. the amount.
  • the amount, therapeutic or prophylactically effective amount, dose, starting dose and the like of the compound to be administered refer to the amount of a specific compound, for example, specifically a certain benzene represented by the formula (I). a heterocyclic compound, a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite or prodrug thereof, specific androgen receptor pathway modulator or specific one or more A therapeutic agent, rather than a combination of multiple compounds.
  • the compound administered to each subject (herein referred to as a benzoheterocyclic compound represented by the formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic thereof
  • a therapeutically or prophylactically effective amount of a stereoisomer, an isotope compound, one of a metabolite and a prodrug, an androgen receptor pathway modulator or other therapeutic agent is from about 0.005 to about 1000 mg/day, from about 0.0.
  • l to about 500 mg / day from about 0.01 to about 250 mg / day, from about 0.01 To about 100 mg/day, from about 0.1 to about 100 mg/day, from about 0.5 to about 100 mg/day, from about 1 to about 100 mg/day, from about 0.01 to about 50 mg/day, from about 0.1 to about 50 mg/ Days, from about 0.5 to about 50 mg/day, from about 1 to about 50 mg/day, from about 0.02 to about 25 mg/day or from about 0.05 to about 10 mg/day.
  • a therapeutically or prophylactically effective amount (herein referred to as a benzoheterocyclic compound of the formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomeric
  • a prophylactic or therapeutically effective amount of one of a conformation, an isotope compound, a metabolite, and a prodrug, an androgen receptor pathway modulator or other therapeutic agent, is about 0.01, about 0.05, about 0.1, about 0.2, about 0.3, About 0.4, about 0.5, about 0.6, about 0.8, about 1, about 2, about 5, about 10, about 15, about 20, about 25, about 30, about 40, about 45, about 50, about 60, about 70 , about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900 or about 1000 mg/day/subject.
  • the combination, pharmaceutical composition or combination kit according to the invention may be used alone, or with ultrasound therapy, radiation therapy (abbreviated as radiotherapy) or Radioimmunotherapy or the like may be used in combination with one or more other pharmacologically active therapeutic agents (hereinafter referred to as "other active agents").
  • other active agents pharmacologically active therapeutic agents
  • the amount and type of other active agent will depend on the disease, condition or condition to be treated or prevented; the severity of the disease, condition or condition; factors of the subject to whom the composition is administered, such as age, weight, physical condition Etc.; route of administration, etc.
  • the other active agent may be a naturally occurring, semi-synthetic or synthetic compound.
  • the other active agent may be a small molecule, such as a synthetic organic or inorganic molecule; or a larger molecule or biomolecule, such as a pharmacologically active protein or nucleic acid.
  • the other active agent may be one of a chemotherapeutic agent, an anti-angiogenic drug (also known as an angiogenesis inhibitor), an immunomodulator, an immunotherapeutic agent, a monoclonal antibody, a polyclonal antibody, and a kinase inhibitor. kind or more.
  • chemotherapeutic agent that is, a chemical synthetic drug.
  • Chemotherapeutic agents are currently the main drugs for the treatment of tumors and certain autoimmune diseases. Commonly used are: epirubicin, doxorubicin, daunorubicin, mitomycin, fluorouracil deoxynucleotides and the like.
  • An anti-angiogenic drug inhibits neovascularization by inhibiting proangiogenic growth factors, growth factor receptors, and downstream signaling pathways, thereby inhibiting tumor growth and metastasis, including vascular endothelial growth inhibitors and receptors.
  • Immunomodulators are drugs that enhance, promote and regulate immune function, and have a role in the treatment of immune dysfunction, certain secondary immunodeficiency diseases and certain malignant tumors. According to the function of immunomodulators, they are mainly classified into immunosuppressants and immunopotentiators. The former is used for anti-inflammatory, anti-autoimmune, anti-allergic, anti-graft rejection and anti-tumor, the latter for anti-infective, anti-allergic and anti-tumor.
  • anti-generation Xie drugs cycloheximide A, thiazolidine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus and mirazolabine, etc.
  • glucocorticoids monoclonal antibodies (anti-TNF -alpha/receptor, anti-IFN- ⁇ , and anti-CD25 single-hang, etc.), cytokines IFN- ⁇ , IL-10 and TGF- ⁇ , chemical agents (levipidine and 5-HT3 receptor antagonists) ), non-strain anti-inflammatory drugs, nucleic acids, statin anti-lipid drugs, HMG coenzyme A reductase inhibitors, plants (Terrata, Cordyceps sinensis extract FTY720, ⁇ , ⁇ , etc.) and others Biological products (cholera toxin B subunit, sNTB-A-Fc fusion protein, CMV-IkappaB
  • immune enhancers including cytokines (interferon alpha, interferon gamma, thymosin and thymus 5 peptide, G-CSF/GM-CSF, IL-2, IL-12, recombinant human erythropoietin, epidermal cells).
  • cytokines interferon alpha, interferon gamma, thymosin and thymus 5 peptide
  • G-CSF/GM-CSF IL-2
  • IL-12 recombinant human erythropoietin, epidermal cells.
  • growth factors chemokine intercellular adhesion molecule-1, vascular cell adhesion molecule-1, P-selectin and other intercellular adhesion molecules, etc.
  • biological products [IVIG, transfer factor, immune ribonucleic acid, bacteria and their extracts (Bacillus Calmette-Guer and its extracts, defatted and delipidated milk M.
  • vaccae vaccine other bacterial extracts, low calcium response V or V antigen LcrV, Vibrio cholerae product Zot and Mycobacterium, etc.
  • plant drugs Polysaccharides, saponins and other botanical ingredients, etc., chemical preparations (levamisole, cimetidine, pidotimod, NS-398 imiprazole, Propagermanium and liposomes, etc.), micronutrients (vitamin A/C/ D, trace elements iron, zinc, selenium) and other (macrolide antibiotics, aminophylline).
  • Immunotherapy refers to modulating a subject's immune response to produce a desired therapeutic effect.
  • the immunotherapeutic agent refers to modulating the subject's immune system when administered to a subject, sufficient to ultimately reduce symptoms associated with adverse immune responses. Or a drug that ultimately reduces the symptoms caused by increasing the required immune response.
  • a monoclonal antibody refers to an antibody that is highly uniform and uniquely directed against a particular antigenic epitope produced by a single B cell clone.
  • Polyclonal antibodies refer to the use of an antigen-immune receptor comprising multiple antigenic determinants, which stimulates multiple B-cell clones of the body to produce different antibodies against multiple epitopes.
  • kinases are a class of enzymes that transfer a phosphate group from a high-energy donor molecule (such as ATP) to a specific target molecule (the substrate); this process is called phosphorylation; a kinase inhibitor is a class that can be combined. A kinase that reduces its activity.
  • active agents include, but are not limited to, daratumumab, elotuzumab, palbociclib, panobinostat, nivolumab, pembrolizumab, pemetrexed, topotecan (topotecan), doxorubicin, and bortezole Rice (bortezomib), gemcitabine, dacarbazine, biaxin, vincristine, azacitidine, CAR-T, rituximab ), trastuzumab, PD-1 inhibitor, PD-L1 inhibitor, HDAC inhibitor, androgen receptor pathway modulator other than the aforementioned androgen receptor pathway modulator, docetaxel (docetaxel), clofarabine injection, Ublituximab, romidepsin, BTK inhibitor, red blood cell growth hormone, eltrombopag, One or more of minocycline and melphalan.
  • active agents include, but are not limited to, dar
  • androgen receptor pathway modulator includes androgen inhibitors, androgen receptor inhibitors, androgen biosynthesis inhibitors, and other drugs that affect the androgen receptor pathway.
  • Hormonal is a type of chemical substance that is produced by certain tissues of the normal body and then diffused into the blood, transported by the blood to other tissues of the body, and exerts a special physiological role. Hormonal compounds include synthetic or natural hormonal chemicals.
  • salt, composition, excipient, etc. it is meant that the salt, composition, excipient, and the like are generally non-toxic, safe, and suitable for use by a subject, preferably A mammalian subject, more preferably a human subject.
  • salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, hydrogen sulfates, phosphates, acid phosphates, isonicotinic acid Salt, lactate, salicylate, acid citrate, tartrate, oleate, tannic acid, pantothenate, hydrogen tartrate, ascorbate, succinate, maleate, gentisinate , fumarate, gluconate, glucuronate, sugar, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, besylate , p-toluenesulfonate and pamoate (ie, 1-1-methylene-bis(2-hydroxy-3-naphthoate)
  • Suitable base salts include, but are not limited to, aluminum salts, calcium salts, lithium salts, magnesium salts, potassium salts, sodium salts, zinc salts, barium salts, and diethanolamine salts.
  • Suitable base salts include, but are not limited to, aluminum salts, calcium salts, lithium salts, magnesium salts, potassium salts, sodium salts, zinc salts, barium salts, and diethanolamine salts.
  • the term "metabolite” refers to an active substance produced by a change in the chemical structure experienced by a drug molecule in vivo, which is typically a derivative of the aforementioned drug molecule, which may also be chemically modified.
  • polymorph refers to one or more crystal structures formed by the different arrangement of molecules in the lattice space upon crystallization.
  • the term "eutectic” refers to a multi-component system in which one or more API (active pharmaceutical ingredient) molecules and one or more guest (or coformer) molecules are present.
  • the API molecule and the guest (or coformer) molecule can also exist as a solid at room temperature when alone in its pure form (in order to distinguish the eutectic from the solvate or hydrate). Salts in which significant or complete proton exchange occurs between the API molecule and the guest molecule are excluded from this particular definition.
  • the API and co-formation interact through hydrogen bonding and possibly other non-covalent interactions. It may be noted that the eutectic itself may form solvates, including hydrates.
  • the guest (or co-form) refers to other physiologically acceptable acid, base, or nonionic compounds.
  • solvate refers to a compound of formula (I), a pharmaceutically acceptable salt thereof, a crystalline form, A crystalline form of a eutectic, stereoisomer, isotope compound, metabolite or prodrug that also contains one or more solvent molecules incorporated into the crystal structure.
  • the solvate may include a stoichiometric or non-stoichiometric amount of solvent, and the solvent molecules in the solvent may be present in an ordered or non-ordered arrangement. Solvates containing non-stoichiometric amounts of solvent molecules may result from the solvate losing at least a portion, but not all, of the solvent molecules.
  • a solvate is a hydrate, meaning that the crystalline form of the compound further comprises water molecules.
  • the term "prodrug” refers to a derivative of a compound comprising a biologically reactive functional group such that under biological conditions (in vitro or in vivo), the bioreactive functional group can be cleaved from the compound or otherwise reacted to provide the Compound.
  • the prodrug is inactive, or at least less active than the compound itself, such that the compound does not exert its activity until it is cleaved from the biologically reactive functional group.
  • the bioreactive functional group can be hydrolyzed or oxidized under biological conditions to provide the compound.
  • a prodrug can comprise a biohydrolyzable group
  • biohydrolyzable groups include, but are not limited to, biohydrolyzable phosphates, biohydrolyzable esters, biohydrolyzable amides, biohydrolyzable carbonates, Biohydrolyzable carbamate and biohydrolyzable ureide.
  • the compound of the formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotopic compound, metabolite or prodrug thereof in the combination of the present invention may contain one or more Symmetric center ("stereoisomer").
  • stereoisomer refers to enantiomers, diastereomers, epimers, endo-exo isomers, steric hindrance All stereoisomers of atropisomers, regioisomers, cis- and trans-isomers, and the like.
  • stereoisomers herein also include “pure stereoisomers” and “enriched stereoisomers” or “racemates” of the various stereoisomers described above. These stereoisomers can be isolated, purified and enriched by asymmetric synthesis or chiral separation methods including, but not limited to, thin layer chromatography, rotary chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc. It is obtained by chiral separation by bonding (chemical bonding, etc.) or salt formation (physical bonding, etc.) with other chiral compounds.
  • pure stereoisomer herein is meant a stereoisomer of the compound in question having a mass content of not less than 95% relative to other stereoisomers of the compound.
  • enriched stereoisomer herein is meant that the stereoisomer of the compound in question has a mass content of not less than 50% relative to the other stereoisomers of the compound.
  • racemate herein is meant that the mass of one stereoisomer of the compound in question is equal to the mass content of the other stereoisomers of the compound.
  • D denotes deuterium-enriched hydrogen and H denotes non-deuterium-enriched hydrogen.
  • ⁇ Enriched compound means a compound of the formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite or prodrug thereof.
  • the abundance of ⁇ at any relevant site is greater than its natural abundance at this site (0.0156%). Therefore, in the "enriched” compound, the abundance of any of its related sites can be Can be in the range of more than 0.0156% to 100%.
  • An example of a method for obtaining a ruthenium-enriched compound is to synthesize a compound by exchanging hydrogen with hydrazine or enriching the starting material with hydrazine.
  • the non- ⁇ enriched sites may also omit the symbol H, as is known in the art.
  • H hydrogen or protium
  • D 2, 2 H, or deuterium
  • T 3 H or tritium
  • isotopic compound means that the compound of the formula (I) of the present invention, a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, metabolite or prodrug thereof contains one or Multiple natural or non-natural abundance of atomic isotopes.
  • Non-natural abundance of atomic isotopes including, but not limited to, hydrazine ( 2 H or D), hydrazine ( 3 H or T), iodine-125 ( 125 I), phosphorus-32 ( 32 P), carbon-13 ( 13 C) Or carbon-14 ( 14 C).
  • the aforementioned isotopic compounds can also be used as therapeutic or diagnostic agents (i.e., in vivo developers), or as research tools. All isotopic variations of the compounds of the invention, whether or not they are radioactive, are included within the scope of the invention.
  • isotopic enrichment refers to a compound of formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotope compound, metabolite, prodrug thereof, Or multiple non-naturally abundant atomic isotopes.
  • “Isotopic enrichment” also refers to a compound of formula (I), a pharmaceutically acceptable salt, solvate, crystal form, eutectic, stereoisomer, isotopic compound, metabolite, or prodrug compound thereof having at least one of Non-natural abundance isotope atom.
  • the term "subject” or “patient” refers to any animal that is or has been administered a compound or composition according to an embodiment of the invention, which is superior to mammals and optimal for humans.
  • the term "mammal” as used herein includes any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., which are optimal for humans.
  • the terms “subject” and “patient” are used interchangeably herein.
  • treating refers to amelioration, prevention, or reversal of a disease or condition, or at least one discernible symptom thereof, for example, by reducing or stabilizing the symptoms of a cancer or condition.
  • “treating” or “treating” refers to the improvement, prevention, or reversal of at least one measurable physical parameter of a disease or condition being treated that may not be recognized in a mammal.
  • “treating” or “treating” refers to slowing the progression of a disease or condition, or physical, such as the identification of stable symptoms, or physiological, for example, stabilization of body parameters. , or both.
  • “treating” or “treating” refers to delaying the onset of a disease or condition.
  • the combination, pharmaceutical composition, or combination kit is administered as a preventative measure.
  • preventing or “preventing” refers to reducing the risk of obtaining a given disease or condition.
  • the specified combination, pharmaceutical composition or combination kit is administered to the subject as a preventative measure, such as a subject having a family history or predisposition to cancer or an autoimmune disease.
  • therapeutically effective amount means capable of causing a biological or medical reaction in a tissue system, animal or human.
  • the therapeutically effective amount is an amount effective to treat, ameliorate, or prevent cancer, a condition, or an undesirable blood vessel.
  • prophylactically effective amount refers to an amount of an active compound or agent that is capable of inhibiting the onset of a condition in a subject (as sought by a researcher, veterinarian, medical practitioner, or other clinician).
  • a prophylactically effective amount of a compound refers to an amount of the therapeutic agent used alone or in combination with other therapeutically active compounds that provides a therapeutic benefit in the treatment or prevention of a disease, disorder or condition.
  • the structure of the other therapeutic agent is as follows:
  • the reagents used in the present invention are all commercially available, and the compound of the formula (I) and the androgen receptor pathway modulator of the present invention may be Those skilled in the art can be synthesized according to synthetic methods well known in the art, or published literature or patents.
  • the compound of formula (I) in the present invention can be prepared according to the methods disclosed in WO9803502, WO2008039489 or WO2011100380, etc.
  • the bulk pathway modulator can be prepared according to the methods disclosed in WO2013087004, WO2014190895, WO2011029392, CN201010120494.9, WO2011029392 or WO2014036897.
  • a positive progressive effect of the present invention is that the combination of the present invention is more effective in inhibiting prostate cancer than the use of each component alone.
  • Test B001 the above-mentioned androgen receptor pathway modulator, the above-mentioned other therapeutic agents alone or in combination with each other on Vcap cells (androgen receptor-positive prostate cancer cells) (ATCC, Cat. No. CRL-2876) Inhibition of proliferation.
  • the specific experimental operation is as follows. 5 ⁇ 10 3 Vcap cells per well were inoculated into a 96-well culture plate (Corning, catalog number CLS3903) containing a specific medium and placed at 37 ° C, 5% CO 2 , incubator The culture was carried out for 24 hours. The test compound was formulated into a 150 mM stock solution in DMSO (Sigma, Cat. No.
  • test compound is used alone or in combination to treat the cells.
  • Other therapeutic agents come from: stellyl acetate (selleck, catalog number S2246), Galeterone (Selleck, catalog number S2803), ODM-201 (Kangpu Biomedical Technology (Shanghai) Co., Ltd.) and prednisone (Selleck) , catalog number S1622).
  • the concentration settings for each test compound are shown in the experimental results table below. After that, add 100 ⁇ l to each well.
  • the cell activity assay reagent (Promega, Cat. No. G7570) was mixed on a shaker for 10 minutes to induce cell lysis.
  • the 96-well plate was allowed to stand at room temperature for 10 minutes to stabilize the luminescence signal.
  • a white base film was attached to the bottom of the plate and an EnSpire plate was used.
  • Data processing was performed by Graphpad/Prism and Calcusyn software to calculate the average cell proliferation inhibition rate or survival rate of each compound.
  • Table 1 including Table 1 Part I. and Table 1 Part II.
  • Table 2 including Table 2 Part I. and Table 2 Part II. Two parts).
  • Table 1 (including Table 1 Part I. and Table 1 Part II.) reflects the test compound used alone or separately with B001 or The effect of a combination of other therapeutic agents (including prednisone, Galeterone, abiraterone acetate, ODM-201) on the survival of Vcap cells. Since Table 1 contains more content, it is divided into two parts: Table 1Part I. and Table 1Part II.
  • Table 2 (including Table 2 Part I. and Table 2 Part II.) demonstrates the combination of test compounds with B001 and other therapeutic agents (including prednisone, Galeterone, abiraterone acetate, ODM-201) to Vcap The effect of cell viability. Due to the large content of Table 2, it is divided into two parts: Table 2Part I. and Table 2Part II.
  • Vcap cell viability test compound alone or in combination with B001 or other therapeutic agents (including prednisone, Galeterone, abiraterone acetate, ODM-201)
  • Vcap cell viability test compound alone or in combination with B001 or other therapeutic agents (including prednisone, Galeterone, abiraterone acetate, ODM-201)
  • Table 1Part I. and Table 1Part II. show: test compounds (AR2-2, AR2-1, AR2-3, AR2-4, AR3-1, AR3-4, AR3-2, AR3-3, The combination of AR2-5, AR1-1, AR1-2) and B001 has outstanding effects.
  • 1 ⁇ M of AR2-2 alone has a Vcap cell survival rate of 65.7%
  • 1 ⁇ M of AR2-2 and 1 ⁇ M has a Vcap cell survival rate decreased to 49.536% when B001 was used.
  • test compounds (AR2-2, AR2-1, AR2-3, AR2-4, AR3-1, AR3-4, AR3-2, AR3-3, AR2-5, AR1-1, AR1-2) and others
  • therapeutic agents including prednisone, Galeterone, abiraterone acetate, ODM-201 was not effective.
  • Vcap cell viability test compound combination with B001 and other therapeutic agents (including prednisone, Galeterone, abiraterone acetate, ODM-201)
  • Vcap cell viability test compound combination with B001 and other therapeutic agents (including prednisone, Galeterone, abiraterone acetate, ODM-201)
  • test compounds (AR2-2, AR2-1, AR2-3, AR2-4, AR3-1, AR3-4, AR3-2, AR3-3, The combination of AR2-5, AR1-1, AR1-2) and B001 is outstanding; when the test compound is combined with B001 and other therapeutic agents (including prednisone, Galeterone, abiraterone acetate, ODM-201), the other The presence of the therapeutic agent does not affect the combined effect of the test compound with B001.
  • other therapeutic agents including prednisone, Galeterone, abiraterone acetate, ODM-201
  • Vcap cell survival rate was 65.7% when 1 ⁇ M of AR2-2 was used alone (refer to Table 1 Part I.), and Vcap cell survival rate was 49.536% when 1 ⁇ M of AR2-2 was combined with 1 ⁇ M B001 (refer to Table 1 Part I.), 1 ⁇ M Vcap cell survival rate was 50.5% when AR2-2 was combined with 1 ⁇ M B001 and 1 ⁇ M prednisone.
  • Vcap cell survival rate was 43.6% when 1 ⁇ M AR2-2 was combined with 1 ⁇ M B001 and 1 ⁇ M Galeterone, 1 ⁇ M AR2-2 and 1 ⁇ M.
  • Vcap cell survival rate was 47.4% when B001 was combined with 1 ⁇ M abiraterone acetate.
  • Vcap cell survival rate was 47.4% when 1 ⁇ M AR2-2 was combined with 1 ⁇ M B001 and 1 ⁇ M ODM-201, 1 ⁇ M AR2-2 and 1 ⁇ M B001 and Vcap cell survival rate was 46.2% when 1 ⁇ M prednisone and 1 ⁇ M Galeterone were combined. Vcap cell survival rate was 46.4% when 1 ⁇ M AR2-2 was combined with 1 ⁇ M B001 and 1 ⁇ M prednisone and 1 ⁇ M abiraterone acetate. 1 ⁇ M AR2 The Vcap cell viability was -46.9% when used in combination with 1 [mu]M B001 and 1 [mu]M prednisone and 1 [mu]M ODM-201.

Abstract

本发明公开了一种治疗前列腺癌的组合、药物组合物及治疗方法。本发明公开的组合包含通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，以及雄激素受体通路调节剂。本发明的组合、其药物组合物及治疗方法能够更有效地抑制前列腺癌。

Description

一种治疗前列腺癌的组合、药物组合物及治疗方法 技术领域
本发明涉及一种治疗前列腺癌的组合、药物组合物及治疗方法。
背景技术
前列腺癌是男性生殖系统常见的恶性肿瘤。据世界卫生组织国际癌症研究机构统计，2012年全球新诊断的前列腺癌患者为110万，约占新增癌症病例总数的15％，成为全球范围内男性第二常见的癌症。在美国，前列腺癌发病率在所有恶性肿瘤中居第一位，死亡率居第二位，仅次于肺癌。中国前列腺癌患者的发病率虽远低于西方国家，但近年来呈显著增长趋势，已在男性泌尿系肿瘤中排名第一，且发现多在晚期。
前列腺癌细胞需要包括睾酮在内的雄激素支持才能生长。因此，前列腺癌的靶向治疗策略主要针对雄激素的合成及其与雄激素受体的结合。例如，2012年8月被美国FDA批准上市的治疗前列腺癌药物恩杂鲁胺(Enzalutamide)是一种小分子雄激素受体拮抗剂，它通过竞争性抑制雄激素与其受体的结合最终抑制雄激素受体信号通路，进而达到治疗去势耐受前列腺癌的效果。
恩杂鲁胺(Enzalutamide)在临床研究中也出现了一些副作用，如虚弱或疲劳、腰背痛、腹泻、关节痛、潮热、组织肿胀、肌肉骨骼疼痛、头痛、上呼吸道感染、头晕、压迫脊髓和马尾神经综合征、肌无力、睡眠困难、下呼吸道感染、血尿、刺痛、焦虑和高血压等。
而对于癌症的治疗，临床上常采用联合用药方式以提高治疗效果，例如多西紫杉醇与强的松联合用于治疗前列腺癌。但是，人们在探索新的联合治疗方案时也会遇到很大挫折，典型的例子之一是，虽然多西紫杉醇与强的松联合可以治疗前列腺癌(Tannock et al.N.Eng.J.Med.(2004),351,1502-1512)，但是，在一项临床研究中，用多西紫杉醇、强的松、来那度胺三者联合的治疗方案却以失败告终(Petrylak et al.Lancet Oncol.(2015)16-4,417-425)。需要同时指出的是，多个II期临床研究结果也表明，来那度胺单独用于治疗前列腺癌的临床效果并不理想(Xing et al.Asian Pac.J.Cancer Prev.(2015)16-9,3969-3972)。因此，探索前列腺癌的联合用药方式以提高疗效、降低毒副作用成为本领域亟需要解决的技术问题。
发明内容
本发明提供了一种治疗前列腺癌的组合、药物组合物及治疗方法。本发明的治疗前列腺癌的组合、药物组合物、治疗方法能够更有效地抑制前列腺癌。
本发明提供了一种治疗前列腺癌的组合，其包含通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，以及雄激素受体通路调节剂；
Figure PCTCN2017073380-appb-000001
通式(I)中，n1为0或1；
L1和L3独立地为
Figure PCTCN2017073380-appb-000002
CH2、CHD、CD2、
Figure PCTCN2017073380-appb-000003
或
Figure PCTCN2017073380-appb-000004
L2为CD2、CHD或CH2；
X为NH、ND或O；
R1、R2和R3独立地为H或D；
Z为
Figure PCTCN2017073380-appb-000005
其中，R4为H、D、CH3、CH2D、CHD2或CD3；R5、R6、R7、R8和R9独立地为H或D；用*标注的碳为不对称中心；
R10为H、D或
Figure PCTCN2017073380-appb-000006
其中R1’、R2’、R3’、R4’和R5’独立地选自H、D、或取代或未取代的(C1-C12)烷基；
所述的取代的(C1-C12)烷基中的取代基选自下列基团中的一个或多个：D、(C2-C20)杂环烷基、氘代(C2-C20)杂环烷基、(C1-C12)烷基取代的(C2-C20)杂环烷基或氘代(C1-C12)烷基取代的(C2-C20)杂环烷基；
当所述的取代的(C1-C12)烷基中的取代基为多个时，所述的取代基相同或不同；
所述的(C2-C20)的杂环烷基、所述的氘代(C2-C20)杂环烷基、所述的(C1-C12)烷基取代 的(C2-C20)杂环烷基或所述的氘代(C1-C12)烷基取代的(C2-C20)杂环烷基中所述的(C2-C20)杂环烷基中的杂原子选自O、N和S中的一个或多个；
当通式(I)中n1为0，X为NH或ND，L1为
Figure PCTCN2017073380-appb-000007
CH2、CHD或CD2；L3为
Figure PCTCN2017073380-appb-000008
时，R10为H或D；
当通式(I)中n1为0，X为NH或ND，L1为
Figure PCTCN2017073380-appb-000009
且L3为
Figure PCTCN2017073380-appb-000010
Figure PCTCN2017073380-appb-000011
时，R10为H或D；
当通式(I)中n1为1，L1为CH2、CHD或CD2，L3为
Figure PCTCN2017073380-appb-000012
时，R10为所述的
Figure PCTCN2017073380-appb-000013
D表示氘富集的氢，H表示非氘富集的氢；
所述的雄激素受体通路调节剂选自下列化合物中的一种：
Figure PCTCN2017073380-appb-000014
Figure PCTCN2017073380-appb-000015
Figure PCTCN2017073380-appb-000016
本发明所述的通式(I)中，所述的不对称中心较佳地是指(S)构型碳、(R)构型碳或者消旋体。
本发明所述的通式(I)中，所述的Z较佳地为下列任一结构：
Figure PCTCN2017073380-appb-000017
Figure PCTCN2017073380-appb-000018
Figure PCTCN2017073380-appb-000019
Z更佳地为下列结构
Figure PCTCN2017073380-appb-000020
其中，用*标注的碳为不对称中心，所述的不对称中心、H和D的定义均如前所述。
本发明所述的通式(I)中，所述的(C2-C20)的杂环烷基、所述的氘代(C2-C20)杂环烷基、所述的(C1-C12)烷基取代的(C2-C20)杂环烷基或所述的氘代(C1-C12)烷基取代的(C2-C20)杂环烷基中所述的(C2-C20)杂环烷基较佳地是指杂原子为N或O，杂原子数为1-2个的(C2-C6)杂环烷基。所述的(C2-C6)杂环烷基较佳地为吗啉基(例如
Figure PCTCN2017073380-appb-000021
)。所述的(C1-C12)烷基取代的(C2-C20)杂环烷基或所述的氘代(C1-C12)烷基取代的(C2-C20)杂环烷基中所述的(C1-C12)烷基较佳地为(C1-C4)烷基。所述的(C1-C4)烷基较佳地为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基。
本发明所述的通式(I)中所述的取代或未取代的(C1-C12)烷基较佳地为取代或未取代 的(C1-C4)烷基。所述的取代或未取代的(C1-C4)烷基较佳地为取代或未取代的甲基、取代或未取代的乙基、取代或未取代的正丙基、取代或未取代的异丙基、取代或未取代的正丁基、取代或未取代的异丁基或者取代或未取代的叔丁基。所述的取代的(C1-C4)烷基较佳地为
Figure PCTCN2017073380-appb-000022
通式(I)中，所述的
Figure PCTCN2017073380-appb-000023
较佳地为
Figure PCTCN2017073380-appb-000024
Figure PCTCN2017073380-appb-000025
本发明所述的通式(I)所示的苯并杂环化合物较佳地为下列任一化合物：
Figure PCTCN2017073380-appb-000026
Figure PCTCN2017073380-appb-000027
本发明所述的组合中，较佳地，所述的通式(I)所示的苯并杂环化合物选自B001、F001、K001或D108。
本发明所述的组合中，较佳地，所述的雄激素受体通路调节剂为下列任一化合物：AR1-1、AR1-2、AR2-1、AR2-2、AR2-3、AR2-4、AR2-5、AR3-1、AR3-2、AR3-3、AR3-4。
在本发明的一些实施例中，所述的组合较佳地包括通式(I)所示的苯并杂环化合物和雄激素受体通路调节剂：所述的通式(I)所示的苯并杂环化合物选自B001、F001、K001或D108；所述的雄激素受体通路调节剂选自AR1-1、AR1-2、AR1-3、AR1-4、AR2-1、AR2-2、AR2-3、AR2-4、AR2-5、AR2-6、AR2-7、AR2-8、AR2-9、AR2-10、AR2-11、AR2-12、AR2-13、AR2-14、AR2-15、AR2-16、AR2-17、AR2-18、AR2-19、AR2-20、AR2-21、AR2-22、AR2-23、AR2-24、AR2-25、AR2-26、AR2-27、AR3-1、AR3-2、AR3-3、AR3-4、AR3-5、AR3-6、AR3-7、AR3-8和AR3-9中的一种；所述的雄激素受体通路调节剂较佳地选自AR1-1、AR1-2、AR2-1、AR2-2、AR2-3、AR2-4、AR2-5、AR3-1、AR3-2、AR3-3和AR3-4中的一种。
在本发明的一些实施例中，所述的组合更佳地为如下任一种组合：“B001或F001或 K001或D108”和AR1-1的组合、“B001或F001或K001或D108”和AR1-2的组合、“B001或F001或K001或D108”和AR1-3的组合、“B001或F001或K001或D108”和AR1-4的组合、“B001或F001或K001或D108”和AR2-1的组合、“B001或F001或K001或D108”和AR2-2的组合、“B001或F001或K001或D108”和AR2-3的组合、“B001或F001或K001或D108”和AR2-4的组合、“B001或F001或K001或D108”和AR2-5的组合、“B001或F001或K001或D108”和AR2-6的组合、“B001或F001或K001或D108”和AR2-7的组合、“B001或F001或K001或D108”和AR2-8的组合、“B001或F001或K001或D108”和AR2-9的组合、“B001或F001或K001或D108”和AR2-10的组合、“B001或F001或K001或D108”和AR2-11的组合、“B001或F001或K001或D108”和AR2-12的组合、“B001或F001或K001或D108”和AR2-13的组合、“B001或F001或K001或D108”和AR2-14的组合、“B001或F001或K001或D108”和AR2-15的组合、“B001或F001或K001或D108”和AR2-16的组合、“B001或F001或K001或D108”和AR2-17的组合、“B001或F001或K001或D108”和AR2-18的组合、“B001或F001或K001或D108”和AR2-19的组合、“B001或F001或K001或D108”和AR2-20的组合、“B001或F001或K001或D108”和AR2-21的组合、“B001或F001或K001或D108”和AR2-22的组合、“B001或F001或K001或D108”和AR2-23的组合、“B001或F001或K001或D108”和AR2-24的组合、“B001或F001或K001或D108”和AR2-25的组合、“B001或F001或K001或D108”和AR2-26的组合、“B001或F001或K001或D108”和AR2-27的组合、“B001或F001或K001或D108”和AR3-1的组合、“B001或F001或K001或D108”和AR3-2的组合、“B001或F001或K001或D108”和AR3-3的组合、“B001或F001或K001或D108”和AR3-4的组合、“B001或F001或K001或D108”和AR3-5的组合、“B001或F001或K001或D108”和AR3-6的组合、“B001或F001或K001或D108”和AR3-7的组合、“B001或F001或K001或D108”和AR3-8的组合、“B001或F001或K001或D108”和AR3-9的组合。
上述的组合，以“B001或F001或K001或D108”和AR1-1的组合为例说明，其表示B001和AR1-1的组合、F001和AR1-1的组合、K001和AR1-1的组合、或、D108和AR1-1的组合，本领域技术人员根据该解释可以理解上述其他组合所表示的含义。
本发明所述的组合还可以进一步包括其他治疗剂，所述的其他治疗剂选自阿比特龙、乙酸阿比特龙酯、Galeterone、ODM201、强的松(Prednisone)、阿比特龙和强的松、乙酸阿比特龙酯和强的松、Galeterone和强的松、和、ODM201和强的松，中的任一组。
因此，本发明所述的组合较佳地包括通式(I)所示的苯并杂环化合物、雄激素受体通 路调节剂和其他治疗剂：所述的通式(I)所示的苯并杂环化合物选自B001、F001、K001或D108；所述的雄激素受体通路调节剂选自AR1-1、AR1-2、AR1-3、AR1-4、AR2-1、AR2-2、AR2-3、AR2-4、AR2-5、AR2-6、AR2-7、AR2-8、AR2-9、AR2-10、AR2-11、AR2-12、AR2-13、AR2-14、AR2-15、AR2-16、AR2-17、AR2-18、AR2-19、AR2-20、AR2-21、AR2-22、AR2-23、AR2-24、AR2-25、AR2-26、AR2-27、AR3-1、AR3-2、AR3-3、AR3-4、AR3-5、AR3-6、AR3-7、AR3-8和AR3-9中的一种；所述的雄激素受体通路调节剂较佳地选自AR1-1、AR1-2、AR2-1、AR2-2、AR2-3、AR2-4、AR2-5、AR3-1、AR3-2、AR3-3和AR3-4中的一种；所述的其他治疗剂选自阿比特龙、乙酸阿比特龙酯、Galeterone、ODM201、强的松(Prednisone)、阿比特龙和强的松、乙酸阿比特龙酯和强的松、Galeterone和强的松、和、ODM201和强的松，中的任一组。
在本发明的一些实施例中，所述的组合较佳地为如下任一组合：“B001或F001或K001或D108”和AR1-1和阿比特龙的组合、“B001或F001或K001或D108”和AR1-2和阿比特龙的组合、“B001或F001或K001或D108”和AR2-1和阿比特龙的组合、“B001或F001或K001或D108”和AR2-2和阿比特龙的组合、“B001或F001或K001或D108”和AR2-3和阿比特龙的组合、“B001或F001或K001或D108”和AR2-4和阿比特龙的组合、“B001或F001或K001或D108”和AR2-5和阿比特龙的组合、“B001或F001或K001或D108”和AR3-1和阿比特龙的组合、“B001或F001或K001或D108”和AR3-2和阿比特龙的组合、“B001或F001或K001或D108”和AR3-3和阿比特龙的组合、“B001或F001或K001或D108”和AR3-4和阿比特龙的组合；“B001或F001或K001或D108”和AR1-1和阿比特龙酯的组合、“B001或F001或K001或D108”和AR1-2和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-1和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-2和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-3和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-4和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-5和阿比特龙酯的组合、“B001或F001或K001或D108”和AR3-1和阿比特龙酯的组合、“B001或F001或K001或D108”和AR3-2和阿比特龙酯的组合、“B001或F001或K001或D108”和AR3-3和阿比特龙酯的组合、“B001或F001或K001或D108”和AR3-4和阿比特龙酯的组合；“B001或F001或K001或D108”和AR1-1和Galeterone的组合、“B001或F001或K001或D108”和AR1-2和Galeterone的组合、“B001或F001或K001或D108”和AR2-1和Galeterone的组合、“B001或F001或K001或D108”和AR2-2和Galeterone的组合、“B001或F001或K001或D108”和AR2-3和Galeterone的组合、“B001或F001或K001或D108”和 AR2-4和Galeterone的组合、“B001或F001或K001或D108”和AR2-5和Galeterone的组合、“B001或F001或K001或D108”和AR3-1和Galeterone的组合、“B001或F001或K001或D108”和AR3-2和Galeterone的组合、“B001或F001或K001或D108”和AR3-3和Galeterone的组合、“B001或F001或K001或D108”和AR3-4和Galeterone的组合；“B001或F001或K001或D108”和AR1-1和ODM201的组合、“B001或F001或K001或D108”和AR1-2和ODM201的组合、“B001或F001或K001或D108”和AR2-1和ODM201的组合、“B001或F001或K001或D108”和AR2-2和ODM201的组合、“B001或F001或K001或D108”和AR2-3和ODM201的组合、“B001或F001或K001或D108”和AR2-4和ODM201的组合、“B001或F001或K001或D108”和AR2-5和ODM201的组合、“B001或F001或K001或D108”和AR3-1和ODM201的组合、“B001或F001或K001或D108”和AR3-2和ODM201的组合、“B001或F001或K001或D108”和AR3-3和ODM201的组合、“B001或F001或K001或D108”和AR3-4和ODM201的组合；“B001或F001或K001或D108”和AR1-1和强的松的组合、“B001或F001或K001或D108”和AR1-2和强的松的组合、“B001或F001或K001或D108”和AR2-1和强的松的组合、“B001或F001或K001或D108”和AR2-2和强的松的组合、“B001或F001或K001或D108”和AR2-3和强的松的组合、“B001或F001或K001或D108”和AR2-4和强的松的组合、“B001或F001或K001或D108”和AR2-5和强的松的组合、“B001或F001或K001或D108”和AR3-1和强的松的组合、“B001或F001或K001或D108”和AR3-2和强的松的组合、“B001或F001或K001或D108”和AR3-3和强的松的组合、“B001或F001或K001或D108”和AR3-4和强的松的组合；“B001或F001或K001或D108”和AR1-1和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR1-2和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-1和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-2和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-3和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-4和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-5和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR3-1和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR3-2和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR3-3和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR3-4和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR1-1和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR1-2和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001 或D108”和AR2-1和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-2和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-3和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-4和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-5和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR3-1和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR3-2和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR3-3和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR3-4和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR1-1和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR1-2和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR2-1和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR2-2和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR2-3和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR2-4和Galeterone和强的松的组合、”B001或F001或K001或D108”和AR2-5和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR3-1和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR3-2和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR3-3和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR3-4和Galeterone和强的松的组合；“B001或F001或K001或D108”和AR1-1和ODM201和强的松的组合、“B001或F001或K001或D108”和AR1-2和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-1和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-2和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-3和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-4和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-5和ODM201和强的松的组合、“B001或F001或K001或D108”和AR3-1和ODM201和强的松的组合、“B001或F001或K001或D108”和AR3-2和ODM201和强的松的组合、“B001或F001或K001或D108”和AR3-3和ODM201和强的松的组合、“B001或F001或K001或D108”和AR3-4和ODM201和强的松的组合。
上述的组合，以“B001或F001或K001或D108”和AR1-1和阿比特龙的组合为例说明，其表示“B001和AR1-1和阿比特龙”的组合、“F001和AR1-1和阿比特龙”的组合、“K001和AR1-1和阿比特龙”的组合、或、“D108和AR1-1和阿比特龙”的组合，本领域技术人员根据该解释应当理解上述其他组合所表示的含义。
所述组合中的各组分可同时使用或分开使用(例如顺序使用)；当所述组合中的各组分同时使用时，所述组合中的各组分可均匀混合(即各组分的混合物)。
本发明中，术语“组分”是指本发明组合中的组分，即通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，雄激素受体通路调节剂，或者其他治疗剂。
本发明还提供了一种药物组合物，其包含上述的组合和一种或多种药用辅料。
一方面，本发明提供的药物组合物，其可包含上述通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，上述雄激素受体通路调节剂，和，一种或多种药用辅料。
另一方面，本发明提供的药物组合物，其可包含上述通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，上述雄激素受体通路调节剂，上述其他治疗剂，和，一种或多种药用辅料。
所述的药用辅料可为药物生产领域中广泛采用的那些辅料。辅料主要用于提供一个安全、稳定和功能性的药物组合物，还可以提供方法，使受试者接受给药后活性成分以所期望速率溶出，或促进受试者接受组合物给药后活性成分得到有效吸收。所述的药用辅料可以是惰性填充剂，或者提供某种功能，例如稳定该组合物的整体pH值或防止组合物活性成分的降解。所述的药用辅料可以包括下列辅料中的一种或多种：粘合剂、助悬剂、乳化剂、稀释剂、填充剂、成粒剂、胶粘剂、崩解剂、润滑剂、抗粘着剂、助流剂、润湿剂、胶凝剂、吸收延迟剂、溶解抑制剂、增强剂、吸附剂、缓冲剂、螯合剂、防腐剂、着色剂、矫味剂和甜味剂。
本领域已知的制备药物组合物的方法包括但不限于常规混合、溶解、造粒、乳化、磨细、包封、包埋或冻干工艺。例如，本发明的药物组合物可以通过混合通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，雄激素受体通路调节剂，和药用辅料来制备。或者，本发明的药物组合物可以通过混合通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，雄激素受体通路调节剂，其他治疗剂，和药用辅料来制备。
本发明所述的药物组合物可以配制成任何形式用于给药，包括注射(静脉内)、粘膜、口服(固体和液体制剂)、吸入、眼部、直肠、局部或胃肠外(输注、注射、植入、皮下、静脉内、动脉内、肌内)给药。本发明的药物组合物还可以是控释或延迟释放剂型。固体 口服制剂的实例包括但不限于粉末、胶囊、囊片、软胶囊剂、丸剂和片剂。口服或粘膜给药的液体制剂实例包括但不限于悬浮液、乳液、酏剂和溶液。局部给药用制剂的实例包括但不限于乳剂、凝胶剂、软膏剂、乳膏剂、贴剂、糊剂、泡沫剂、洗剂、滴剂或血清制剂。胃肠外给药的制剂实例包括但不限于注射用溶液、可以溶解或悬浮在药学上可接受载体中的干制剂、注射用悬浮液和注射用乳剂。所述的药物组合物的其它合适制剂的实例包括但不限于滴眼液和其他眼科制剂；气雾剂：如鼻腔喷雾剂或吸入剂；适于胃肠外给药的液体剂型；栓剂以及锭剂。
再一方面，本发明还提供了一种组合药盒，其包含药物组合物A和药物组合物B；
所述的药物组合物A包含上述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，和，一种或多种药用辅料；所述的药物组合物B包含上述的雄激素受体通路调节剂和一种或多种药用辅料。
所述的组合药盒还可以包含药物组合物C，所述的药物组合物C包含上述的其他治疗剂和一种或多种药用辅料。
较佳地，所述的药物组合物A中所述的“通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种”、所述的药物组合物B中所述的“雄激素受体通路调节剂”、所述的药物组合物C中所述的“其他治疗剂”及它们所形成的组合如上所述。
所述组合药盒中的各个药物组合物可以同时使用或分开使用(例如顺序使用)。
所述组合药盒中，所述的“药用辅料”的定义同上。
本发明中，术语“活性成分”是指本发明药物组合物或组合药盒中的活性成分，即通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，雄激素受体通路调节剂，其他治疗剂，或者，它们所形成的上述组合。
上述组合、上述药物组合物、或上述的组合药盒可用于预防和/或治疗前列腺癌。所述的前列腺癌较佳地为去势抵抗性前列腺癌。
再一方面，本发明还提供了上述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，在制备用于和上述的雄激素受体通路调节剂联合预防和/或治疗前列腺癌的药物中的应用。
本发明还提供了上述的雄激素受体通路调节剂，在制备用于和上述的通式(I)所示的 苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种联合预防和/或治疗前列腺癌的药物中的应用。
又一方面，本发明还提供了上述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，在制备用于和上述的雄激素受体通路调节剂、以及上述的其他治疗剂联合预防和/或治疗前列腺癌的药物中的应用。
本发明还提供了上述的雄激素受体通路调节剂，在制备用于和上述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种、以及上述的其他治疗剂联合预防和/或治疗前列腺癌的药物中的应用。
本发明还提供了上述的其他治疗剂，在制备用于和上述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种、以及、上述的雄激素受体通路调节剂联合预防和/或治疗前列腺癌的药物中的应用。
在本发明所述的应用中，上述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，上述的雄激素受体通路调节剂，和，上述其他治疗剂可以同时或者分开施用(例如顺序施用)。
在上述的应用中，所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种、所述的雄激素受体通路调节剂、所述的其他治疗剂以及它们所形成的组合如上所述。
再一方面，本发明还提供了一种预防和/或治疗前列腺癌的方法，包括向所需患者施用治疗或预防有效量的上述的组合。所述的前列腺癌可为去势抵抗性前列腺癌。
在一个实施例中，所述预防和/或治疗前列腺癌的方法，包括向所需患者施用治疗或预防有效量的上述通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，和，治疗或预防有效量的上述的雄激素受体通路调节剂。
其中，上述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，和，上述的雄激素受体通路调节剂可以同时或者分开施用(例如顺序施用)。
在本发明的一些实施例中，所述的预防和/或治疗前列腺癌的方法较佳地包括向所需 患者施用治疗或预防有效量的上述通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物或前药中的一种，治疗或预防有效量的上述雄激素受体通路调节剂，以及，治疗或预防有效量的上述其他治疗剂。
其中，上述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，上述的雄激素受体通路调节剂，和，上述其他治疗剂可以同时或者分开施用(例如顺序施用)。
在所述的预防和/或治疗前列腺癌的方法中，所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种、所述的雄激素受体通路调节剂、所述的其他治疗剂以及它们所形成的组合如上所述。
在本发明所述的组合、药物组合物、组合药盒、应用、或预防和/或治疗前列腺癌的方法中，所述的通式(I)所示的苯并杂环化合物与所述的雄激素受体通路调节剂的摩尔比可根据本领域常规进行选择，例如1:0.1-1:100，例如1:1-1:50，例如1:1-1:10。
在本发明所述的组合、药物组合物、组合药盒、应用、或预防和/或治疗前列腺癌的方法中，当还进一步含其他治疗剂时，所述的其他治疗剂的用量不做特殊的限定，例如所述的其他治疗剂与所述的雄激素受体通路调节剂的摩尔比可以是1:0.1-1:100，例如1:0.5-1:50，例如1:1-1:10。
在本发明所述的组合、药物组合物、组合药盒、应用、或预防和/或治疗前列腺癌的方法中，所述的通式(I)所示的苯并杂环化合物与所述的雄激素受体通路调节剂的用量可以根据本领域常规进行选择，例如通式(I)所示的苯并杂环化合物的物质的量可以是1-100μM，例如1-50μM，例如1-10μM；雄激素受体通路调节剂的物质的量可以是1-300μM，例如1-100μM，例如1-10μM。
在本发明所述的组合、药物组合物、组合药盒、应用、或预防和/或治疗前列腺癌的方法中，当还进一步含有其他治疗剂时，所述的其他治疗剂的用量不做特殊的限定，例如所述的其他治疗剂的物质的量可以是1-300μM，例如1-100μM，例如1-10μM。
当将本发明的组合中的各组分给予受试者以治疗或预防疾病、病症或病况时，组合中的各组分可通过相同的途径给药，也可通过不同的途径给药。可通过本文描述的任何途径给药，包括但不限于口服、吸入、注射、眼部、粘膜、直肠、乳剂、脂质体、长效植入或持续缓释方法。具体给药途径将依赖于治疗剂本身及制剂，以及需预防或治疗的疾病、病症或病况。根据本公开内容，本领域中一名普通技术人员的技能水平足以确定其给药途径。本发明的组合中的各组分，可以在一段时间(给药周期)内给予受试者，其后 是一段不给予化合物的时期(非给药周期)。可以重复所需次数的给药周期和非给药周期。给药周期或者非给药周期的所需长度和次数将取决于正在治疗或预防的疾病、病症或病况的类型和/或严重程度，以及受试者个体的性别、年龄、体重和其他参数(例如，受试者个体的生物学、身体和生理状况等)。在本发明的组合中的各组分，可以在一段时间内同时给予受试者，还可以在一段时间内先后给予受试者。根据本文件公开的内容本领域普通技术人员的技术水平将足以确定给药周期和/或非给药周期的适当长度和次数。
本文所述的治疗方法可使用任何合适的方法将本发明的组合中的各组分给予受试者，包括注射、经粘膜、口服、吸入、眼部、直肠、长效植入、脂质体、乳剂或持续释放方法。
本领域技术人员会认识到，本发明的组合、药物组合物或组合药盒中的各组分或者活性成分的治疗或预防有效量可以随着因素的不同而不同，对于特定受试者，如年龄、饮食、健康等，寻求治疗或预防的症状或疾病、病症或病况的严重程度以及并发症和类型，所用制剂等。根据本发明公开内容，本领域普通技术人员将能够很容易地确定需给予受试者的治疗或预防有效量，以便在受试者中引起期望的生物学或医学响应。
在另一个实施例中，本发明所述的组合、药物组合物、组合药盒、应用、或预防和/或治疗前列腺癌的方法中，雄激素受体通路调节剂或其他治疗剂的治疗或预防有效量可低于不给予本发明通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物或前药时的有效量。
本发明中，涉及的所施用的化合物的量、治疗或预防有效量、剂量、起始剂量等均是指具体某一个化合物的量，例如具体地某一个通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物或前药、具体某一个雄激素受体通路调节剂或具体某一个其他治疗剂，而非多个化合物的组合。
本发明中方法中所用雄激素受体通路调节剂或其他治疗剂的治疗或预防有效量和给药指导可见本文引用的专利和公布的专利申请以及Wells et al,eds.,Pharmacotherapy Handbook,2nd Edition,Appleton and Lange,Stamford,Conn.(2000)；PDR Pharmacopoeia,Tarascon Pocket Pharmacopoeia 2000,Deluxe Edition,Tarascon Publishing,Loma Linda,Calif.(2000)和其它医学文献。
在某些实施方式中，给予每个受试者的化合物(此处是指通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种、雄激素受体通路调节剂或其他治疗剂)的治疗或预防有效量为从约0.005至约1000mg/天，从约0.0l至约500mg/天，从约0.0l至约250mg/天，从约0.0l 至约100mg/天，从约0.1至约100mg/天，从约0.5至约100mg/天，从约1至约100mg/天，从约0.0l至约50mg/天，从约0.1至约50mg/天，从约0.5至约50mg/天，从约1至约50mg/天，从约0.02至约25mg/天或从约0.05至约l0mg/天。
在某些实施方式中，治疗或预防有效量(此处是指通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种、雄激素受体通路调节剂或其他治疗剂的预防或治疗有效量)是约0.01、约0.05、约0.1、约0.2、约0.3、约0.4、约0.5、约0.6、约0.8、约1、约2、约5、约10、约15、约20、约25、约30、约40、约45、约50、约60、约70、约80、约90、约100、约150、约200、约250、约300、约350、约400、约450、约500、约550、约600、约650、约700、约750、约800、约850、约900或约1000mg/每天/受试者。
在本文所述的任何方法中，包括但是不限于前述的治疗方法、应用等，根据本发明的组合、药物组合物或组合药物盒可单独使用，或与超声疗法、放射疗法(简称放疗)或放射免疫疗法等配合使用，还可与一种或多种其它具有药理学活性的治疗剂(以下简称“其它活性剂”)联合使用。其它活性剂的量和类型将取决于要进行治疗或预防的疾病、病症或病况；疾病、病症或病况的严重程度；接受组合物给药的受试者的因素，如年龄、体重、身体状况等；给药途径等。根据本发明的实施例，其它活性剂可以是天然存在的、半合成的或合成的化合物。在另一个实施例中，其它活性剂可以是小分子，如合成的有机或无机分子；或较大的分子或生物分子，例如具有药理活性的蛋白质或核酸。在另一个实施例中，其它活性剂可以是化疗剂、抗血管生成药物(又称血管生成抑制剂)、免疫调节剂、免疫治疗剂、单克隆抗体、多克隆抗体和激酶抑制剂中的一种或多种。
化疗剂(化学治疗剂)，即化学合成药物。化疗剂是目前治疗肿瘤及某些自身免疫性疾病的主要药物，常用的有：表阿霉素、阿霉素、柔红霉素、丝裂霉素、氟尿嘧啶脱氧核苷酸等。
抗血管生成药物是指通过抑制促血管生成的生长因子、生长因子受体及下游信号通路等抑制新生血管生成，从而抑制肿瘤的生长和转移的发生，主要包括血管内皮生长抑制剂、受体酪氨酸激酶抑制剂、PI3K/AKT/mTOR通路抑制剂、作用于VEGF-A、VEGF-B和胎盘生长因子的重组融合蛋白(例如阿柏西普)、重组人血管内皮抑素等。
免疫调节剂是增强、促进和调节免疫功能的药物，对治疗免疫功能低下，某些继发性免疫缺陷病和某些恶性肿瘤等有一定作用。按照免疫调节剂的功能，主要分为免疫抑制剂和免疫增强剂。前者用于抗炎症、抗自身免疫反应、抗过敏、抗移植排斥反应和抗肿瘤，后者用于抗感染、抗过敏和抗肿瘤。属于免疫抑制剂的药物种类繁多，包括抗代 谢药物(环袍菌素A、硫唑漂吟、环磷酰胺、甲氨蝶吟、霉酚酸酯、他克莫司和米唑拉宾等)、糖皮质激素、单克隆抗体(抗TNF-alpha/受体、抗IFN-γ，和抗CD25单杭等)、细胞因子IFN-β、,IL-10和TGF-β、化学制剂(来氟米特和5-HT3受体拮杭剂)、非苗体类抗炎药、核酸类、他丁类抗脂药、HMG辅酶A还原酶抑制剂、植物类(雷公藤、冬虫夏草提取物FTY720、青高素和帕吠琳等)和其他生物制品(霍乱毒素B亚单位、sNTB-A-Fc融合蛋白、CMV-IkappaBa载体抑制剂和B7-HI抑制剂等)。免疫增强剂的品种同样繁多，包括细胞因子(干扰素α、干扰素γ、胸腺肽和胸腺5肽、G-CSF/GM-CSF、IL-2、IL-12、重组人红细胞生成素、表皮细胞生长因子、趋化因子细胞间黏附分子-1、血管细胞黏附分子-1，P-选择素及其他细胞间黏附分子等)、生物制品[IVIG、转移因子、免疫核糖核酸、细菌及其提取物(卡介苗及其提取物、脱脂脱糖脂母牛分枝杆菌菌苗、其他细菌提取物、低钙反应V或V抗原LcrV，霍乱弧菌的产物Zot和分歧杆菌等)]、植物类药物(多糖、皂苷及其他植物成分等)、化学制剂(左旋咪唑、甲氰咪呱、匹多莫德、NS-398咪啥莫特、Propagermanium和脂质体等)、微量营养素(维生素A/C/D、微量元素铁、锌、硒)和其他(大环内酯类抗生素、氨茶碱)。
免疫治疗指调节受试者的免疫反应，使其产生需要的治疗效果，免疫治疗剂指当给予受试者时，调节该受试者的免疫系统，足以最终减少与不利的免疫反应相关的症状或者最终减轻由于增加所需的免疫反应而导致的症状的药物。
单克隆抗体是指由单一B细胞克隆产生的高度均一、仅针对某一特定抗原表位的抗体。
多克隆抗体是指用一种包含多种抗原决定簇的抗原免疫受体，可刺激机体多个B细胞克隆产生针对多种抗原表位的不同抗体。
在生物化学里，激酶是一类从高能供体分子(如ATP)转移磷酸基团到特定靶分子(受质)的酶；这一过程谓之磷酸化；激酶抑制剂是指一类可以结合激酶并降低其活性的分子。
其它活性剂包括但不限于：daratumumab、elotuzumab、palbociclib、panobinostat、nivolumab、pembrolizumab、培美曲塞(pemetrexed)、托泊替康(拓扑替康)(topotecan)、阿霉素(doxorubicin)、硼替佐米(bortezomib)、吉西他滨(gemcitabine)、达卡巴嗪(dacarbazine)、克拉霉素(biaxin)、长春新碱(vincristine)、阿糖胞苷(azacitidine)、CAR-T、利妥昔单抗(rituximab)、曲妥珠单抗(trastuzumab)、PD-1抑制剂、PD-L1抑制剂、HDAC抑制剂、除前述雄激素受体通路调节剂以外的雄激素受体通路调节剂、多西他赛(docetaxel)、氯法拉滨注射液、Ublituximab、romidepsin、BTK抑制剂、红血球生长激素、eltrombopag、 米诺四环素和美法仑(melphalan)中的一种或多种。
本文所用术语“雄激素受体通路调节剂”包括雄激素抑制剂、雄激素受体抑制剂、雄激素生物合成抑制剂以及其它影响雄激素受体通路的药物。
术语“激素”是由正常机体某些组织产生，然后弥散入血液，由血液循环运输到机体其他组织，发挥特殊生理作用的一类化学物质。激素类化合物包括人工合成的或天然的激素类化学物质。
如本文中所用，当提到具体盐、组合物、辅料等“药学上可接受的”时，是指该盐、组合物、辅料等一般无毒、安全，并且适合于受试者使用，优选哺乳动物受试者，更优选为人受试者。
本文所用术语“药学上可接受的盐”指药学上可接受的有机或无机盐。示例性盐包括但不限于：硫酸盐、柠檬酸盐、乙酸盐、草酸盐、氯化物、溴化物、碘化物、硝酸盐、硫酸氢盐、磷酸盐、酸式磷酸盐、异烟酸盐、乳酸盐、水杨酸盐、酸式柠檬酸盐、酒石酸盐、油酸盐、单宁酸盐、泛酸盐、酒石酸氢盐、抗坏血酸盐、琥珀酸盐、马来酸盐、gentisinate、富马酸盐、葡糖酸盐、葡糖醛酸盐、糖酸盐、甲酸盐、苯甲酸盐、谷氨酸盐、甲烷磺酸盐、乙烷磺酸盐、苯磺酸盐、对甲苯磺酸盐和双羟萘酸盐(即1-1-亚甲基-双(2-羟基-3-萘甲酸盐))。本发明中所用化合物可与各种氨基酸形成药学上可接受的盐。合适的碱盐包括但不限于铝盐、钙盐、锂盐、镁盐、钾盐、钠盐、锌盐、铋和二乙醇胺盐。药学上可接受的盐的综述见Handbook of Pharmaceutical Salts:Properties,Selection,and Use(P.Heinrich Stahl and Camille G.Wermuth,ed.,Wiley-VCH,2002)。
如本文所用，术语“代谢物”是指药物分子在体内所经历的化学结构的变化后产生的活性物质，该活性物质一般为前述药物分子的衍生物，其还可被化学修饰。
如本文所用，术语“晶型(polymorph)”是指在结晶时，分子在晶格空间的排列不同而形成的一种或多种晶体结构。
如本文所用，术语“共晶”是指其中存在一种或多种API(活性药物成分)分子和一种或多种客体(或助形成物)分子的多组分体系。在共晶中，当独自为其纯品形式(为了使共晶区别于溶剂化物或水合物)时，API分子和客体(或助形成物)分子在室温下也都可以以固体存在。从这种特定的定义中排除了其中在API分子和客体分子之间发生显著的或完全的质子交换的盐。在共晶中，API和助形成物通过氢键和可能的其他非共价的相互作用而发生相互作用。可注意到，共晶本身可能形成溶剂化物，包括水合物。客体(或助形成物)是指其他生理上可接受的酸、碱、非离子化合物。
如本文所用，术语“溶剂化物”是指通式(I)化合物、其药学上可接受的盐、晶型、 共晶、立体异构体、同位素化合物、代谢物或前药的一种晶体形式，它还包含一种或多种融入晶体结构中的溶剂分子。溶剂化物可包括化学计量量或非化学计量量的溶剂，并且溶剂中的溶剂分子可能以有序或非有序排列的形式存在。含有非化学计量量溶剂分子的溶剂化物可能是溶剂化物至少丢失一部分(但并非全部)溶剂分子得到的。在一个特定实施例中，一种溶剂化物是一种水合物，意味着化合物的结晶形式进一步包括水分子。
如本文所用，术语“前药”是指包含生物反应官能团的化合物的衍生物，使得在生物条件下(体外或体内)，生物反应官能团可从化合物上裂解或以其他方式发生反应以提供所述化合物。通常，前药无活性，或者至少比化合物本身活性低，使得直到将所述化合物从生物反应官能团上裂解后才能发挥其活性。生物反应官能团可在生物条件下水解或氧化以提供所述化合物。例如，前药可包含可生物水解的基团，可生物水解的基团实例包括但不限于可生物水解的磷酸盐、可生物水解的酯、可生物水解的酰胺、可生物水解的碳酸酯、可生物水解的氨基甲酸酯和可生物水解的酰脲。有关前药的综述参见，例如，J.Rautio et al.,Nature Reviews Drug Discovery(2008)7,255-270and Prodrugs:Challenges和Rewards(V.Stella et al.ed.,Springer,2007)。
本发明的组合中的通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物或前药可以含有一个或多个不对称中心(“立体异构体”)。如本文所用，术语“立体异构体”是指对映异构体、非对映异构体、差向异构体(epimers)、内向-外向异构体(endo-exo isomers)、阻转异构体(atropisomers)、位向异构体(regioisomers)、顺式-和反式-异构体等在内的所有立体异构体。本文的“立体异构体”也包括前述各种立体异构体的“纯立体异构体”及“富集立体异构体”或“消旋体”。这些立体异构体可以通过不对称合成方法或手性分离法(包括但不限于薄层色谱、旋转色谱、柱色谱、气相色谱、高压液相色谱等)分离、纯化及富集，还可以通过与其它手性化合物成键(化学结合等)或成盐(物理结合等)等方式进行手性拆分获得。本文的“纯立体异构体”是指所涉化合物的一种立体异构体相对于该化合物的其它种立体异构体的质量含量不低于95％。本文的“富集立体异构体”是指所涉化合物的一种立体异构体相对于该化合物的其它种立体异构体的质量含量不低于50％。本文的“消旋体”是指所涉化合物的一种立体异构体的质量含量与该化合物的其它种立体异构体的质量含量相等。
如本文所用，D表示氘富集的氢，H表示非氘富集的氢。“氘富集”化合物意指在通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物或前药的化合物中的任何相关位点处的氘的丰度大于其在该位点处的自然丰度(0.0156％)。因此，在“氘富集”化合物中，其相关位点中的任一者处的氘丰度都可 能在大于0.0156％到100％的范围内。获得氘富集化合物的方法的实例是用氘交换氢或者用氘富集起始物质合成化合物。
根据本领域普通技术知识，非氘富集的位点还可以省略符号H。非氘富集是指自然中的氢，即以H(氢或氕)、D(2H或氘)和T(3H或氚)同位素混合物的形式存在的。
本文所用术语“同位素化合物”是指本发明的通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、代谢物或前药中含有一个或多个天然或非天然丰度的原子同位素。非天然丰度的原子同位素包括但不限于氘(2H或D)、氚(3H或T)、碘-125(125I)、磷-32(32P)、碳-13(13C)或碳-14(14C)。前述同位素化合物还可用作治疗或诊断剂(即，体内显影剂)，或研究工具。本发明的化合物的所有同位素变体，无论是否具有放射性，都包括在本发明的范围内。
本文所用术语“同位素富集”是指通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物、前药中含有一个或多个非天然丰度的原子同位素。“同位素富集”也指通式(I)化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物，或前药化合物中至少含有一个非天然丰度同位素原子。
如本文所用，术语“受试者”或“患者”是指根据本发明的实施例，即将或已经接受了该化合物或组合物给药的任何动物，哺乳动物为优，人类最优。如本文所用，术语“哺乳动物”包括任何哺乳动物。哺乳动物的实例包括但不限于牛、马、羊、猪、猫、狗、小鼠、大鼠、家兔、豚鼠、猴、人等，以人类为最优。术语“受试者”和“患者”在本文中可互换使用。在一个实施例中，“治疗”或“正在治疗”是指疾病或病症或其至少一个可辨别症状的改善、预防或逆转，例如通过减少或稳定癌症或病症症状，治疗癌症。在另一个实施例中，“治疗”或“正在治疗”指正在治疗的疾病或病症的至少一个可测量身体参数的改善、预防或逆转，可能并未在哺乳动物中识别所述疾病或病症。然而在另一个实施例中，“治疗”或“正在治疗”是指减慢疾病或病症的进展，或者是身体上的，例如可辨别症状的稳定，或生理学上的，例如，身体参数的稳定，或两者兼而有之。在另一个实施例中，“治疗”或“正在治疗”是指延迟疾病或病症的发作。
在某些实施例中，组合、药物组合物或组合药盒作为预防措施给药。如本文所用，“预防”或“正在预防”是指降低获得给定疾病或病症的风险。在实施例的优选模式中，将指定组合、药物组合物或组合药盒作为预防措施给予受试者，例如有癌症或自身免疫性疾病家族病史或倾向的受试者。
如本文所用，“治疗有效量”是指能够引起组织系统、动物或人产生生物学或医学反 应(研究员、兽医、医生或其他临床医生正在寻求的)的化合物或组合物的量，其可以包括减轻正在治疗的疾病或病症症状。在一个优选实施例中，治疗有效量是有效治疗、改善治疗或预防癌症、病症或不期望的血管的量。
术语“预防有效量”是指能够抑制受试者中病症发作(研究员、兽医、医生或其它临床医生所寻求的)的活性化合物或药剂的量。化合物的预防有效量是指治疗剂单独使用或联合其它治疗活性化合物所用的量，其在治疗或预防疾病、病症或病况中能够提供治疗益处。
在不违背本领域常识的基础上，上述各优选条件，可任意组合，即得本发明各较佳实例。
如无另外说明，本文所用术语的单数形式“一个”或“一种”也包括复数意义。
如无另外说明，本文使用“或”或“和”指“和/或”。
本文中引用或描述了各种出版物、文章和专利，引用或描述这些参考文献或将其整体并入本文或对之进行的讨论是为了说明本发明的背景，并非是指其中的内容构成了本发明现有技术的一部分。
除非另有定义，本文所用所有技术和科学术语与本发明所属领域的普通技术人员通常理解的含义相同。否则，此处所用的某些术语的含义具有本说明书所设定的含义。
本发明中，所述的其他治疗剂的结构如下：
Figure PCTCN2017073380-appb-000028
本发明所用试剂均市售可得，本发明中式(I)化合物和雄激素受体通路调节剂可由 本领域技术人员根据本领域熟知的合成方法，或已公开的文献或专利合成得到，例如本发明中式(I)化合物可根据WO9803502，WO2008039489或WO2011100380等公开的方法制备得到；所述的雄激素受体通路调节剂可根据WO2013087004、WO2014190895、WO2011029392、CN201010120494.9、WO2011029392或WO2014036897等公开的方法制备得到。
本发明的积极进步效果在于：本发明的组合比各组分单独使用能够更有效地抑制前列腺癌。
具体实施方式
下面通过实施例的方式进一步说明本发明，但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法，按照常规方法和条件，或按照商品说明书选择。
效果实施例1CTG细胞增殖实验：
体外测试评价通式(I)化合物与雄激素受体通路调节剂联用、或通式(I)化合物与雄激素受体通路调节剂和其他治疗剂联用对前列腺癌细胞增殖的抑制作用。
在Vcap细胞(雄激素受体阳性前列腺癌细胞)(ATCC，产品目录号CRL-2876)上测试B001、上述雄激素受体通路调节剂、上述其他治疗剂单用或彼此联用对前列腺癌细胞增殖的抑制作用。具体实验操作如下。按每孔5×103个Vcap细胞，接种至含有特定培养基的底透壁白的96-孔培养板(Corning，产品目录号CLS3903)中，置于37℃，5％CO2，培养箱内培养24小时。测试化合物用DMSO(Sigma，产品目录号276855)配成150mM的储备液，用培养基稀释至所需浓度(DMSO终浓度为0.2％)后加入各孔，2孔/浓度，在37℃，5％CO2培养箱内孵育5天。测试化合物单用或联用处理细胞。其他治疗剂来自：乙酸阿比特龙酯(Selleck，产品目录号S2246),Galeterone(Selleck，产品目录号S2803)，ODM-201(康朴生物医药技术(上海)有限公司)和强的松(Selleck，产品目录号S1622)。每个测试化合物的浓度设置见下述实验结果表。之后，每孔加入100μl 
Figure PCTCN2017073380-appb-000029
细胞活性检测试剂(Promega，产品目录号G7570)，在振板机上混匀10分钟，诱导细胞溶解。将96孔板在室温中放置10分钟，使其发光信号稳定。粘贴白色的底膜于培养板底部，使用EnSpire测板。通过Graphpad/Prism和Calcusyn软件进行数据处理，计算每个化合物的平均细胞增殖抑制率或存活率，具体实验结果见表1(包括表1Part I.和表1Part II.两部分)和表2(包括表2Part I.和表2Part II.两部分)。
表1(包括表1Part I.和表1Part II.两部分)体现了测试化合物单用或分别与B001或 其他治疗剂(包括强的松、Galeterone、乙酸阿比特龙酯、ODM-201)的联合用药对Vcap细胞存活率的影响。由于表1内容较多，分成表1Part I.和表1Part II.两部分。
表2(包括表2Part I.和表2Part II.两部分)体现了测试化合物分别与B001和其他治疗剂(包括强的松、Galeterone、乙酸阿比特龙酯、ODM-201)的联合用药对Vcap细胞存活率的影响。由于表2内容较多，分成表2Part I.和表2Part II.两部分。
表1Part I.Vcap细胞存活率：测试化合物单用或分别与B001或其他治疗剂(包括强的松、Galeterone、乙酸阿比特龙酯、ODM-201)的联合用药
Figure PCTCN2017073380-appb-000030
表1Part II.Vcap细胞存活率：测试化合物单用或分别与B001或其他治疗剂(包括强的松、Galeterone、乙酸阿比特龙酯、ODM-201)的联合用药
Figure PCTCN2017073380-appb-000031
Figure PCTCN2017073380-appb-000032
注解：表1Part I.和表1Part II.的结果显示：测试化合物(AR2-2、AR2-1、AR2-3、AR2-4、AR3-1、AR3-4、AR3-2、AR3-3、AR2-5、AR1-1、AR1-2)与B001联合用药效果突出，例如，根据表1Part I.，1μM的AR2-2单用时Vcap细胞存活率为65.7％，1μM的AR2-2与1μM的B001联用时Vcap细胞存活率降低到49.536％。但测试化合物(AR2-2、AR2-1、AR2-3、AR2-4、AR3-1、AR3-4、AR3-2、AR3-3、AR2-5、AR1-1、AR1-2)与其他治疗剂(包括强的松、Galeterone、乙酸阿比特龙酯、ODM-201)联用时效果不明显。
表2Part I.Vcap细胞存活率：测试化合物分别与B001和其他治疗剂(包括强的松、Galeterone、乙酸阿比特龙酯、ODM-201)的联合用药
Figure PCTCN2017073380-appb-000033
表2Part II.Vcap细胞存活率：测试化合物分别与B001和其他治疗剂(包括强的松、Galeterone、乙酸阿比特龙酯、ODM-201)的联合用药
Figure PCTCN2017073380-appb-000034
Figure PCTCN2017073380-appb-000035
注解：表2Part I.和表2Part II.的结果显示：测试化合物(AR2-2、AR2-1、AR2-3、AR2-4、AR3-1、AR3-4、AR3-2、AR3-3、AR2-5、AR1-1、AR1-2)与B001联合用药效果突出；当测试化合物与B001和其他治疗剂(包括强的松、Galeterone、乙酸阿比特龙酯、ODM-201)联用时，其他治疗剂的存在并不影响测试化合物与B001之间的联合用药效果。例如，1μM的AR2-2单用时Vcap细胞存活率为65.7％(参考表1Part I.)，1μM的AR2-2与1μM B001联用时Vcap细胞存活率为49.536％(参考表1Part I.)，1μM的AR2-2与1μM B001和1μM强的松联用时Vcap细胞存活率为50.5％，1μM的AR2-2与1μM B001和1μM Galeterone联用时Vcap细胞存活率为43.6％，1μM的AR2-2与1μM B001和1μM乙酸阿比特龙酯联用时Vcap细胞存活率为47.4％，1μM的AR2-2与1μM B001和1μM ODM-201联用时Vcap细胞存活率为47.4％，1μM的AR2-2与1μM B001和1μM强的松和1μM Galeterone联用时Vcap细胞存活率为46.2％，1μM的AR2-2与1μM B001和1μM强的松和1μM乙酸阿比特龙酯联用时Vcap细胞存活率为46.4％，1μM的AR2-2与1μM B001和1μM强的松和1μM ODM-201联用时Vcap细胞存活率为46.9％。
虽然以上描述了本发明的具体实施方式，但是本领域的技术人员应当理解，这些仅是举例说明，在不背离本发明的原理和实质的前提下，可以对这些实施方式做出多种变更或修改。因此，本发明的保护范围由所附权利要求书限定。

Claims (15)

  1. 一种治疗前列腺癌的组合，其包含通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，以及雄激素受体通路调节剂；
    Figure PCTCN2017073380-appb-100001
    通式(I)中，n1为0或1；
    L1和L3独立地为
    Figure PCTCN2017073380-appb-100002
    Figure PCTCN2017073380-appb-100003
    L2为CD2、CHD或CH2；
    X为NH、ND或O；
    R1、R2和R3独立地为H或D；
    Z为
    Figure PCTCN2017073380-appb-100004
    其中，R4为H、D、CH3、CH2D、CHD2或CD3；R5、R6、R7、R8和R9独立地为H或D；用*标注的碳为不对称中心；
    R10为H、D或
    Figure PCTCN2017073380-appb-100005
    其中R1’、R2’、R3’、R4’和R5’独立地选自H、D、或取代或未取代的(C1-C12)烷基；
    所述的取代的(C1-C12)烷基中的取代基选自下列基团中的一个或多个：D、(C2-C20)杂环烷基、氘代(C2-C20)杂环烷基、(C1-C12)烷基取代的(C2-C20)杂环烷基或氘代(C1-C12)烷基取代的(C2-C20)杂环烷基；
    当所述的取代的(C1-C12)烷基中的取代基为多个时，所述的取代基相同或不同；
    所述的(C2-C20)的杂环烷基、所述的氘代(C2-C20)杂环烷基、所述的(C1-C12)烷基取代的(C2-C20)杂环烷基或所述的氘代(C1-C12)烷基取代的(C2-C20)杂环烷基中所述的(C2-C20) 杂环烷基中的杂原子选自O、N和S中的一个或多个；
    当通式(I)中n1为0，X为NH或ND，L1为
    Figure PCTCN2017073380-appb-100006
    CH2、CHD或CD2；L3为
    Figure PCTCN2017073380-appb-100007
    时，R10为H或D；
    当通式(I)中n1为0，X为NH或ND，L1为
    Figure PCTCN2017073380-appb-100008
    且L3为
    Figure PCTCN2017073380-appb-100009
    Figure PCTCN2017073380-appb-100010
    时，R10为H或D；
    当通式(I)中n1为1，L1为CH2、CHD或CD2，L3为
    Figure PCTCN2017073380-appb-100011
    时，R10为所述的
    Figure PCTCN2017073380-appb-100012
    D表示氘富集的氢，H表示非氘富集的氢；
    所述的雄激素受体通路调节剂选自下列化合物中的一种：
    Figure PCTCN2017073380-appb-100013
    Figure PCTCN2017073380-appb-100014
    Figure PCTCN2017073380-appb-100015
  2. 如权利要求1所述的治疗前列腺癌的组合，其特征在于，通式(I)中，所述的Z为下列任一结构：
    Figure PCTCN2017073380-appb-100016
    Figure PCTCN2017073380-appb-100017
    Figure PCTCN2017073380-appb-100018
    其中，*、H和D的定义如权利要求1所述；
    和/或，通式(I)中，所述的(C2-C20)的杂环烷基、所述的氘代(C2-C20)杂环烷基、所述的(C1-C12)烷基取代的(C2-C20)杂环烷基或所述的氘代(C1-C12)烷基取代的(C2-C20)杂环烷基中，所述的(C2-C20)杂环烷基是指杂原子为N或O，杂原子数为1-2个的(C2-C6)杂环烷基；所述的(C2-C6)杂环烷基较佳地为吗啉基；所述的(C1-C12)烷基取代的(C2-C20)杂环烷基或所述的氘代(C1-C12)烷基取代的(C2-C20)杂环烷基中，所述的(C1-C12)烷基为(C1-C4)烷基；所述的(C1-C4)烷基较佳地为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基；
    和/或，通式(I)中，所述的取代或未取代的(C1-C12)烷基为取代或未取代的(C1-C4)烷基；所述的取代或未取代的(C1-C4)烷基较佳地为取代或未取代的甲基、取代或未取代的乙基、取代或未取代的正丙基、取代或未取代的异丙基、取代或未取代的正丁基、取代或未取代的异丁基或者取代或未取代的叔丁基；所述的取代的(C1-C4)烷基较佳地为
    Figure PCTCN2017073380-appb-100019
    Figure PCTCN2017073380-appb-100020
    和/或，通式(I)中，所述的
    Figure PCTCN2017073380-appb-100021
    为
    Figure PCTCN2017073380-appb-100022
    Figure PCTCN2017073380-appb-100023
  3. 如权利要求2所述的治疗前列腺癌的组合，其特征在于，所述的通式(I)所示的苯并杂环化合物为下列任一化合物：
    Figure PCTCN2017073380-appb-100024
    Figure PCTCN2017073380-appb-100025
    优选B001、F001、K001或D108。
  4. 如权利要求1-3中任一项所述的治疗前列腺癌的组合，其特征在于，所述的雄激素受体通路调节剂为下列任一化合物：AR1-1、AR1-2、AR2-1、AR2-2、AR2-3、AR2-4、AR2-5、AR3-1、AR3-2、AR3-3、AR3-4。
  5. 如权利要求3所述的治疗前列腺癌的组合，其特征在于，所述的通式(I)所示的苯并杂环化合物和所述的雄激素受体通路调节的组合为如下任一种组合：“B001或F001或K001或D108”和AR1-1的组合、“B001或F001或K001或D108”和AR1-2的组合、“B001或F001或K001或D108”和AR1-3的组合、“B001或F001或K001或D108”和AR1-4的组合、“B001或F001或K001或D108”和AR2-1的组合、“B001或F001或K001或D108”和AR2-2的组合、“B001或F001或K001或D108”和AR2-3的组合、“B001或F001或K001或D108”和AR2-4的组合、“B001或F001或K001或D108”和AR2-5的组合、“B001或F001或K001或D108”和AR2-6的组合、“B001或F001或K001或D108”和AR2-7的组合、“B001或F001或K001或D108”和AR2-8的组合、“B001或F001或K001或D108”和AR2-9的组合、“B001或F001或K001或D108”和AR2-10的组合、“B001或F001或K001或D108”和AR2-11的组合、“B001或F001或K001或D108”和AR2-12的组合、“B001或F001或K001或D108”和AR2-13的组合、“B001或F001或K001或D108”和AR2-14的组合、“B001或F001或K001或D108”和AR2-15的组合、“B001或F001或K001或D108”和AR2-16的组合、“B001或F001或K001或D108”和AR2-17的组合、“B001或F001或K001或D108”和AR2-18的组 合、“B001或F001或K001或D108”和AR2-19的组合、“B001或F001或K001或D108”和AR2-20的组合、“B001或F001或K001或D108”和AR2-21的组合、“B001或F001或K001或D108”和AR2-22的组合、“B001或F001或K001或D108”和AR2-23的组合、“B001或F001或K001或D108”和AR2-24的组合、“B001或F001或K001或D108”和AR2-25的组合、“B001或F001或K001或D108”和AR2-26的组合、“B001或F001或K001或D108”和AR2-27的组合、“B001或F001或K001或D108”和AR3-1的组合、“B001或F001或K001或D108”和AR3-2的组合、“B001或F001或K001或D108”和AR3-3的组合、“B001或F001或K001或D108”和AR3-4的组合、“B001或F001或K001或D108”和AR3-5的组合、“B001或F001或K001或D108”和AR3-6的组合、“B001或F001或K001或D108”和AR3-7的组合、“B001或F001或K001或D108”和AR3-8的组合、“B001或F001或K001或D108”和AR3-9的组合。
  6. 如权利要求5所述的治疗前列腺癌的组合，其特征在于，所述的通式(I)所示的苯并杂环化合物和所述的雄激素受体通路调节的组合为如下任一种组合：B001和AR1-1、B001和AR1-2、B001和AR2-1、B001和AR2-2、B001和AR2-3、B001和AR2-4、B001和AR2-5、B001和AR3-1、B001和AR3-2、B001和AR3-3、B001和AR3-4、F001和AR1-1、F001和AR1-2、F001和AR2-1、F001和AR2-2、F001和AR2-3、F001和AR2-4、F001和AR2-5、F001和AR3-1、F001和AR3-2、F001和AR3-3、F001和AR3-4、K001和AR1-1、K001和AR1-2、K001和AR2-1、K001和AR2-2、K001和AR2-3、K001和AR2-4、K001和AR2-5、K001和AR3-1、K001和AR3-2、K001和AR3-3、K001和AR3-4、D108和AR1-1、D108和AR1-2、D108和AR2-1、D108和AR2-2、D108和AR2-3、D108和AR2-4、D108和AR2-5、D108和AR3-1、D108和AR3-2、D108和AR3-3、或、D108和AR3-4。
  7. 如权利要求1-6中任一项所述的治疗前列腺癌的组合，其特征在于，所述的治疗前列腺癌的组合还进一步包括其他治疗剂，所述的其他治疗剂选自阿比特龙、乙酸阿比特龙酯、Galeterone、ODM201、强的松、阿比特龙和强的松、乙酸阿比特龙酯和强的松、Galeterone和强的松、和、ODM201和强的松，中的任一组。
  8. 如权利要求7所述的治疗前列腺癌的组合，其特征在于，所述的通式(I)所示的苯并杂环化合物、所述雄激素受体通路调节剂和所述其他治疗剂的组合为如下任一种组合：“B001或F001或K001或D108”和AR1-1和阿比特龙的组合、“B001或F001或K001或D108”和AR1-2和阿比特龙的组合、“B001或F001或K001或D108”和AR2-1和阿比特龙的组合、“B001或F001或K001或D108”和AR2-2和阿比特龙的组合、“B001 或F001或K001或D108”和AR2-3和阿比特龙的组合、“B001或F001或K001或D108”和AR2-4和阿比特龙的组合、“B001或F001或K001或D108”和AR2-5和阿比特龙的组合、“B001或F001或K001或D108”和AR3-1和阿比特龙的组合、“B001或F001或K001或D108”和AR3-2和阿比特龙的组合、“B001或F001或K001或D108”和AR3-3和阿比特龙的组合、“B001或F001或K001或D108”和AR3-4和阿比特龙的组合；“B001或F001或K001或D108”和AR1-1和阿比特龙酯的组合、“B001或F001或K001或D108”和AR1-2和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-1和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-2和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-3和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-4和阿比特龙酯的组合、“B001或F001或K001或D108”和AR2-5和阿比特龙酯的组合、“B001或F001或K001或D108”和AR3-1和阿比特龙酯的组合、“B001或F001或K001或D108”和AR3-2和阿比特龙酯的组合、“B001或F001或K001或D108”和AR3-3和阿比特龙酯的组合、“B001或F001或K001或D108”和AR3-4和阿比特龙酯的组合；“B001或F001或K001或D108”和AR1-1和Galeterone的组合、“B001或F001或K001或D108”和AR1-2和Galeterone的组合、“B001或F001或K001或D108”和AR2-1和Galeterone的组合、“B001或F001或K001或D108”和AR2-2和Galeterone的组合、“B001或F001或K001或D108”和AR2-3和Galeterone的组合、“B001或F001或K001或D108”和AR2-4和Galeterone的组合、“B001或F001或K001或D108”和AR2-5和Galeterone的组合、“B001或F001或K001或D108”和AR3-1和Galeterone的组合、“B001或F001或K001或D108”和AR3-2和Galeterone的组合、“B001或F001或K001或D108”和AR3-3和Galeterone的组合、“B001或F001或K001或D108”和AR3-4和Galeterone的组合；“B001或F001或K001或D108”和AR1-1和ODM201的组合、“B001或F001或K001或D108”和AR1-2和ODM201的组合、“B001或F001或K001或D108”和AR2-1和ODM201的组合、“B001或F001或K001或D108”和AR2-2和ODM201的组合、“B001或F001或K001或D108”和AR2-3和ODM201的组合、“B001或F001或K001或D108”和AR2-4和ODM201的组合、“B001或F001或K001或D108”和AR2-5和ODM201的组合、“B001或F001或K001或D108”和AR3-1和ODM201的组合、“B001或F001或K001或D108”和AR3-2和ODM201的组合、“B001或F001或K001或D108”和AR3-3和ODM201的组合、“B001或F001或K001或D108”和AR3-4和ODM201的组合；“B001或F001或K001或D108”和AR1-1和强的松的组合、“B001或F001或K001或D108”和AR1-2和强的松的组合、“B001或F001或K001 或D108”和AR2-1和强的松的组合、“B001或F001或K001或D108”和AR2-2和强的松的组合、“B001或F001或K001或D108”和AR2-3和强的松的组合、“B001或F001或K001或D108”和AR2-4和强的松的组合、“B001或F001或K001或D108”和AR2-5和强的松的组合、“B001或F001或K001或D108”和AR3-1和强的松的组合、“B001或F001或K001或D108”和AR3-2和强的松的组合、“B001或F001或K001或D108”和AR3-3和强的松的组合、“B001或F001或K001或D108”和AR3-4和强的松的组合、“B001或F001或K001或D108”和AR1-1和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR1-2和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-1和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-2和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-3和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-4和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR2-5和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR3-1和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR3-2和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR3-3和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR3-4和阿比特龙和强的松的组合、“B001或F001或K001或D108”和AR1-1和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR1-2和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-1和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-2和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-3和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-4和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR2-5和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR3-1和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR3-2和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR3-3和乙酸阿比特龙酯和强的松的组合、“B001或F001或K001或D108”和AR3-4和乙酸阿比特龙酯和强的松的组合；“B001或F001或K001或D108”和AR1-1和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR1-2和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR2-1和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR2-2和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR2-3和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR2-4和Galeterone和强的松的组合、”B001或F001或K001或D108”和AR2-5和Galeterone和强的松的组 合、“B001或F001或K001或D108”和AR3-1和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR3-2和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR3-3和Galeterone和强的松的组合、“B001或F001或K001或D108”和AR3-4和Galeterone和强的松的组合；“B001或F001或K001或D108”和AR1-1和ODM201和强的松的组合、“B001或F001或K001或D108”和AR1-2和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-1和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-2和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-3和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-4和ODM201和强的松的组合、“B001或F001或K001或D108”和AR2-5和ODM201和强的松的组合、“B001或F001或K001或D108”和AR3-1和ODM201和强的松的组合、“B001或F001或K001或D108”和AR3-2和ODM201和强的松的组合、“B001或F001或K001或D108”和AR3-3和ODM201和强的松的组合、“B001或F001或K001或D108”和AR3-4和ODM201和强的松的组合。
  9. 一种药物组合物，其包含如权利要求1-8中任一项所述的组合和一种或多种药用辅料。
  10. 一种组合药盒，其包含药物组合物A和药物组合物B；
    所述的药物组合物A包含权利要求1-6中任一项所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，和，一种或多种药用辅料；所述的药物组合物B包含权利要求1-6任一项所述的雄激素受体通路调节剂和一种或多种药用辅料；
    所述的组合药盒较佳地还包含药物组合物C，所述的药物组合物C包含权利要求7或8所述的其他治疗剂和一种或多种药用辅料。
  11. 权利要求1-6中任一项所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，在制备用于和权利要求1-6任一项所述的雄激素受体通路调节剂联合预防和/或治疗前列腺癌的药物中的应用；
    或者，权利要求1-6任一项所述的雄激素受体通路调节剂，在制备用于和权利要求1-6中任一项所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种联合预防和/或治疗前列腺癌的药物中的应用。
  12. 权利要求1-8中任一项所述的通式(I)所示的苯并杂环化合物、其药学上可接受 的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，在制备用于和权利要求1-8任一项所述的雄激素受体通路调节剂、以及权利要求7或8所述的其他治疗剂联合预防和/或治疗前列腺癌的药物中的应用；
    或者，权利要求1-8任一项所述的雄激素受体通路调节剂，在制备用于和权利要求1-8中任一项所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种、以及权利要求7或8所述的其他治疗剂联合预防和/或治疗前列腺癌的药物中的应用；
    或者，权利要求7或8所述的其他治疗剂，在制备用于和权利要求1-8中任一项所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种、以及、权利要求1-8任一项所述的雄激素受体通路调节剂联合预防和/或治疗前列腺癌的药物中的应用。
  13. 一种预防和/或治疗前列腺癌的方法，包括向所需患者施用治疗或预防有效量的如权利要求1～8中任一项所述的组合。
  14. 权利要求13所述的方法，其特征在于，包括向所需患者施用治疗或预防有效量的权利要求1-6中任一项所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，和，治疗或预防有效量的权利要求1-6所述的雄激素受体通路调节剂；
    或者，包括向所需患者施用治疗或预防有效量的权利要求1-8中任一项所述的通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物或前药，治疗或预防有效量的权利要求1-8任一项所述的雄激素受体通路调节剂，以及，治疗或预防有效量的权利要求7或8所述的其他治疗剂。
  15. 如权利要求14所述的方法，其特征在于，所述的“通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种”、和、所述的“雄激素受体通路调节剂”同时或者分开施用；
    和/或，所述的“通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种”、所述的“雄激素受体通路调节剂”、和、所述的“其他治疗剂”同时或者分开施用；
    和/或，所述的前列腺癌为去势抵抗性前列腺癌。
PCT/CN2017/073380 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法 WO2017067530A2 (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU2017202864A AU2017202864B2 (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
KR1020197026618A KR102125661B1 (ko) 2017-02-13 2017-02-13 전립선암 치료용 조합, 약학 조성물 및 치료 방법
RU2019127449A RU2733950C1 (ru) 2017-02-13 2017-02-13 Комбинация для лечения рака предстательной железы, фармацевтическая композиция и способ лечения
JP2019543848A JP6773915B2 (ja) 2017-02-13 2017-02-13 前立腺癌を治療する組み合わせ、薬物組成物および治療方法
CN201780085859.9A CN110248662B (zh) 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法
PL17718469T PL3581182T3 (pl) 2017-02-13 2017-02-13 Kombinacja lecząca nowotwór złośliwy gruczołu krokowego, kompozycja farmaceutyczna i sposób leczenia
CA3053805A CA3053805C (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
ES17718469T ES2899372T3 (es) 2017-02-13 2017-02-13 Combinación de tratamiento del cáncer de próstata, composición farmacéutica y método de tratamiento
EP17718469.4A EP3581182B1 (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
NZ756412A NZ756412B2 (en) 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
PCT/CN2017/073380 WO2017067530A2 (zh) 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法
US16/482,549 US20200000776A1 (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
ZA2019/05222A ZA201905222B (en) 2017-02-13 2019-08-07 Combination treating prostate cancer, pharmaceutical composition and treatment method
US17/325,468 US20210267946A1 (en) 2017-02-13 2021-05-20 Combination treating prostate cancer, pharmaceutical composition and treatment method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/073380 WO2017067530A2 (zh) 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/482,549 A-371-Of-International US20200000776A1 (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
US17/325,468 Continuation US20210267946A1 (en) 2017-02-13 2021-05-20 Combination treating prostate cancer, pharmaceutical composition and treatment method

Publications (2)

Publication Number Publication Date
WO2017067530A2 true WO2017067530A2 (zh) 2017-04-27
WO2017067530A3 WO2017067530A3 (zh) 2017-12-21

Family

ID=58558089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/073380 WO2017067530A2 (zh) 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法

Country Status (12)

Country Link
US (2) US20200000776A1 (zh)
EP (1) EP3581182B1 (zh)
JP (1) JP6773915B2 (zh)
KR (1) KR102125661B1 (zh)
CN (1) CN110248662B (zh)
AU (1) AU2017202864B2 (zh)
CA (1) CA3053805C (zh)
ES (1) ES2899372T3 (zh)
PL (1) PL3581182T3 (zh)
RU (1) RU2733950C1 (zh)
WO (1) WO2017067530A2 (zh)
ZA (1) ZA201905222B (zh)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
WO2018108147A1 (zh) * 2016-12-16 2018-06-21 康朴生物医药技术（上海）有限公司 一种组合、其应用及治疗方法
WO2018208123A1 (ko) * 2017-05-12 2018-11-15 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2019032840A1 (en) * 2017-08-09 2019-02-14 Druggability Technologies Ip Holdco Limited PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DAROLUTAMIDE
US10287353B2 (en) 2016-05-11 2019-05-14 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-1 inhibitors
US10385131B2 (en) 2016-05-11 2019-08-20 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-L1 inhibitors
WO2019218979A1 (zh) * 2018-05-14 2019-11-21 成都海创药业有限公司 一种hc-1119制剂及其制备方法和用途
CN111514140A (zh) * 2019-02-01 2020-08-11 江苏恒瑞医药股份有限公司 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
JP2021519322A (ja) * 2018-03-29 2021-08-10 ヒノバ ファーマシューティカルズ インコーポレイテッド 重水素化イミダゾリジンジオン化合物とその用途
US11192878B2 (en) 2017-05-12 2021-12-07 Korea Research Institute Of Chemical Technology Piperidine-2,6-dione derivative and use thereof
US11358952B2 (en) 2018-04-23 2022-06-14 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527216A (ja) 2019-04-12 2022-05-31 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬
KR102479869B1 (ko) 2020-06-05 2022-12-21 중앙대학교 산학협력단 당단풍나무 추출물 또는 이의 분획물을 포함하는 전립선암 예방, 치료, 또는 개선용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003502A1 (en) 1996-07-24 1998-01-29 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
WO2008039489A2 (en) 2006-09-26 2008-04-03 Celgene Corporation 5-substituted quinazolinone derivatives as antitumor agents
WO2011029392A1 (en) 2009-09-10 2011-03-17 Youzhi Tong Androgen receptor antagonists and uses thereof
WO2011100380A1 (en) 2010-02-11 2011-08-18 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2013087004A1 (zh) 2011-12-14 2013-06-20 Chen Yuanwei 咪唑二酮类化合物及其用途
WO2014036897A1 (zh) 2012-09-04 2014-03-13 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
WO2014190895A1 (zh) 2013-05-29 2014-12-04 成都海创药业有限公司 咪唑二酮类化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8940719B2 (en) * 2006-07-03 2015-01-27 Academia Sinica Lithocholic acid analogues that inhibit sialyltransferase
WO2011057064A1 (en) * 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
RU2598854C2 (ru) * 2011-03-10 2016-09-27 Сучжоу Кинтор Фармасьютикалз, Инк. Производные тиогидантоина, полезные в качестве антагонистов рецептора андрогена
CA2889756C (en) * 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Thiohydantoin compounds as androgen receptor modulators
US9290475B2 (en) * 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
JP6778114B2 (ja) * 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US10017492B2 (en) * 2014-10-30 2018-07-10 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
WO2017054739A1 (zh) * 2015-09-29 2017-04-06 康朴生物医药技术（上海）有限公司 一种药物组合物及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003502A1 (en) 1996-07-24 1998-01-29 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
WO2008039489A2 (en) 2006-09-26 2008-04-03 Celgene Corporation 5-substituted quinazolinone derivatives as antitumor agents
WO2011029392A1 (en) 2009-09-10 2011-03-17 Youzhi Tong Androgen receptor antagonists and uses thereof
WO2011100380A1 (en) 2010-02-11 2011-08-18 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2013087004A1 (zh) 2011-12-14 2013-06-20 Chen Yuanwei 咪唑二酮类化合物及其用途
WO2014036897A1 (zh) 2012-09-04 2014-03-13 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
WO2014190895A1 (zh) 2013-05-29 2014-12-04 成都海创药业有限公司 咪唑二酮类化合物及其用途

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
"PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000", 2000, TARASCON PUBLISHING
"Prodrugs: Challenges and Rewards", 2007, SPRINGER
J. RAUTIO ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 7, 2008, pages 255 - 270
PETRYLAK ET AL., LANCET ONCOL, vol. 16-4, 2015, pages 417 - 425
See also references of EP3581182A4
TANNOCK ET AL., N. ENG. J. MED., vol. 351, 2004, pages 1502 - 1512
XING ET AL., ASIAN PAC. J. CANCER PREV., vol. 16- 9, 2015, pages 3969 - 3972

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10385130B2 (en) 2016-05-11 2019-08-20 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-1 inhibitors
US11535670B2 (en) 2016-05-11 2022-12-27 Huyabio International, Llc Combination therapies of HDAC inhibitors and PD-L1 inhibitors
US10287353B2 (en) 2016-05-11 2019-05-14 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-1 inhibitors
US10385131B2 (en) 2016-05-11 2019-08-20 Huya Bioscience International, Llc Combination therapies of HDAC inhibitors and PD-L1 inhibitors
WO2018108147A1 (zh) * 2016-12-16 2018-06-21 康朴生物医药技术（上海）有限公司 一种组合、其应用及治疗方法
AU2017376704B2 (en) * 2016-12-16 2021-08-05 Kangpu Biopharmaceuticals, Ltd. Composition, application thereof and treatment method
US10933059B2 (en) 2016-12-16 2021-03-02 Kangpu Biopharmaceuticals. Ltd. Combination, application thereof and treatment method
US11192878B2 (en) 2017-05-12 2021-12-07 Korea Research Institute Of Chemical Technology Piperidine-2,6-dione derivative and use thereof
WO2018208123A1 (ko) * 2017-05-12 2018-11-15 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2019032840A1 (en) * 2017-08-09 2019-02-14 Druggability Technologies Ip Holdco Limited PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE AND DAROLUTAMIDE
WO2019120079A1 (zh) * 2017-12-19 2019-06-27 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
JP2021519322A (ja) * 2018-03-29 2021-08-10 ヒノバ ファーマシューティカルズ インコーポレイテッド 重水素化イミダゾリジンジオン化合物とその用途
US11358952B2 (en) 2018-04-23 2022-06-14 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
US11945804B2 (en) 2018-04-23 2024-04-02 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
WO2019218979A1 (zh) * 2018-05-14 2019-11-21 成都海创药业有限公司 一种hc-1119制剂及其制备方法和用途
JP2021523195A (ja) * 2018-05-14 2021-09-02 ヒノバ ファーマシューティカルズ インコーポレイテッド Ｈｃ−１１１９製剤及びその製造方法と使用
JP7301883B2 (ja) 2018-05-14 2023-07-03 ヒノバ ファーマシューティカルズ インコーポレイテッド Ｈｃ－１１１９製剤及びその製造方法と使用
CN111514140A (zh) * 2019-02-01 2020-08-11 江苏恒瑞医药股份有限公司 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
CN111514140B (zh) * 2019-02-01 2021-09-03 江苏恒瑞医药股份有限公司 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途

Also Published As

Publication number Publication date
JP2020506216A (ja) 2020-02-27
PL3581182T3 (pl) 2022-01-17
US20210267946A1 (en) 2021-09-02
EP3581182A2 (en) 2019-12-18
CA3053805A1 (en) 2017-04-27
RU2733950C1 (ru) 2020-10-08
AU2017202864B2 (en) 2020-04-23
ES2899372T3 (es) 2022-03-11
EP3581182A4 (en) 2020-02-26
KR20190111133A (ko) 2019-10-01
AU2017202864A1 (en) 2019-09-26
WO2017067530A3 (zh) 2017-12-21
CA3053805C (en) 2020-06-30
EP3581182B1 (en) 2021-09-29
US20200000776A1 (en) 2020-01-02
CN110248662A (zh) 2019-09-17
JP6773915B2 (ja) 2020-10-21
KR102125661B1 (ko) 2020-06-22
ZA201905222B (en) 2020-05-27
CN110248662B (zh) 2022-08-16
NZ756412A (en) 2021-01-29

Similar Documents

Publication Publication Date Title
WO2017067530A2 (zh) 一种治疗前列腺癌的组合、药物组合物及治疗方法
RU2705576C2 (ru) Фармацевтическая композиция для предупреждения и/или лечения рака предстательной железы, применение бензогетероциклического соединения и способ предупреждения и/или лечения рака предстательной железы
CA3188171A1 (en) Compositions and methods for treating diseases and disorders
CN110049765B (zh) 一种组合、其应用及治疗方法
US20240139156A1 (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
NZ753549B2 (en) Combination comprising benzoheterocyclic compound and androgen receptor pathway modulator, application thereof and treatment method
NZ756412B2 (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
WO2023220227A1 (en) Treating diseases and disorders with irak4-modifying compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17718469

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3053805

Country of ref document: CA

Ref document number: 2019543848

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197026618

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017718469

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017202864

Country of ref document: AU

Date of ref document: 20170213

Kind code of ref document: A